var title_f39_60_40896="Cervical remodeling";
var content_f39_60_40896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Cervical remodeling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 449px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stages of cervical function during pregnancy and the puerperium. Although the process occurs as a continuum, each stage is characterized by unique biochemical and cellular events.",
"    <div class=\"footnotes\">",
"     iNOS: induced nitric oxide synthase; IL-8: interleukin-8; HA: hyaluronan; GAGs: glycosaminoglycans.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Word RA, Li X-H, Hnat M, Carrick K. Dynamics of cervical remodeling during pregnancy and parturition: Mechanisms and current concepts. Semin Reprod Med 2007; 25:69. Copyright &copy; 2007 Thieme Medical Publishers, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40896=[""].join("\n");
var outline_f39_60_40896=null;
var title_f39_60_40897="PLEVA 1";
var content_f39_60_40897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40897=[""].join("\n");
var outline_f39_60_40897=null;
var title_f39_60_40898="Purpura fulminans";
var content_f39_60_40898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Purpura fulminans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sharply demarcated purpuric lesions were present in this patient with purpura fulminans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40898=[""].join("\n");
var outline_f39_60_40898=null;
var title_f39_60_40899="Acyclovir (topical): Patient drug information";
var content_f39_60_40899=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acyclovir (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/27/1460?source=see_link\">",
"     see \"Acyclovir (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/51/9011?source=see_link\">",
"     see \"Acyclovir (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7908397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7908398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat herpes infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701438",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acyclovir, valacyclovir, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a rubber glove to put on the ointment. This stops the spread of infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12438 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40899=[""].join("\n");
var outline_f39_60_40899=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908397\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908398\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031414\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031413\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031418\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031419\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031421\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031416\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031417\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031422\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031423\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"mobipreview.htm?17/42/18081?source=related_link\">",
"      Acyclovir (ophthalmic): International drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/40/37512?source=related_link\">",
"      Acyclovir (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/48/38660?source=related_link\">",
"      Acyclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/37/2649?source=related_link\">",
"      Acyclovir (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/27/1460?source=related_link\">",
"      Acyclovir (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/51/9011?source=related_link\">",
"      Acyclovir (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_60_40900="MRI urethral diverticulum1";
var content_f39_60_40900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image of female urethral diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2 axial contrast enhanced MR image shows a diverticulum (arrows) wrapped around the urethra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40900=[""].join("\n");
var outline_f39_60_40900=null;
var title_f39_60_40901="Erosive pustular dermatosis of the scalp";
var content_f39_60_40901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Erosive pustular dermatosis of the scalp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Crusted plaques and erosions are present on the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40901=[""].join("\n");
var outline_f39_60_40901=null;
var title_f39_60_40902="Tricuspid regurgitation CW Doppler";
var content_f39_60_40902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation CW Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This echocardiographic still frame demonstrates Doppler interrogation of tricuspid insufficiency to estimate the gradient between the right ventricle and the right atrium. The continuous wave Doppler beam, represented by the dotted cursor line, is directed into the tricuspid insufficiency jet in this parasternal long axis inflow window. Using the modified Bernoulli equation (pressure = 4 [velocity]",
"    <sup>",
"     2",
"    </sup>",
"    ), the Doppler velocity of 3.3 m/sec translates into a gradient between the right atrium and right ventricle of 44 mmHg; adding the estimated right atrial pressure of 10 mmHg, the estimated right ventricular pressure in this patient is 54 mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40902=[""].join("\n");
var outline_f39_60_40902=null;
var title_f39_60_40903="Treatment of metastatic breast cancer in older women";
var content_f39_60_40903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of metastatic breast cancer in older women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/60/40903/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40903/contributors\">",
"     Gretchen Kimmick, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/60/40903/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40903/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/60/40903/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40903/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/60/40903/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in primary and adjuvant treatment for local breast cancer, many patients will experience metastatic disease. In addition, one to five percent of women with breast cancer have metastatic disease at presentation. Although patients with metastatic breast cancer are unlikely to be cured of their disease, survival has improved over time due to improved options for treatment. As an example, compared to women treated from 1991 to 1992, those treated from 1999 to 2001 had a statistically longer survival (median, 22 versus 15 months, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address issues pertinent to systemic antitumor treatment in older women (typically defined as age &gt;65 years) with metastatic breast cancer. General principles that guide treatment of metastatic breast cancer in all populations, as well as more extensive discussions of endocrine therapy and chemotherapy for metastatic disease, are discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/55/21370?source=see_link\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"       \"Assessment of cancer pain\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link\">",
"       \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"       \"Radiation therapy for the management of painful bone metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19464?source=see_link\">",
"       \"Management of brain metastases in breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management principles that guide treatment of metastatic breast cancer in older women are similar to those used to guide treatment of younger women, with few exceptions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Life expectancy, comorbidity, and functional status should be considered when making treatment decisions in the setting of metastatic cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link&amp;anchor=H7#H7\">",
"       \"General principles on the treatment of early stage and locally advanced breast cancer in older women\", section on 'Factors that affect treatment decisions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A comprehensive geriatric assessment may be useful in formulating an appropriate, individualized treatment plan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"       \"Comprehensive geriatric assessment for patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endocrine therapy is almost always chosen as the initial treatment of hormone receptor-positive tumors and in those women with an unknown hormone receptor status. Given the more favorable toxicity profile of endocrine therapy compared to chemotherapy, some experts also administer endocrine therapy as first-line treatment to patients with hormone receptor-negative disease who are too frail for chemotherapy. &nbsp;",
"     </li>",
"     <li>",
"      The appropriate use of chemotherapy should not be withheld solely on the basis of older age. Any decision on the administration of chemotherapy in older women should be individualized based on their tumor and the potential benefits and risks of treatment. The use of a model that can predict patients who may be at an increased risk of severe or fatal toxicity from chemotherapy may help identify appropriate patients for systemic treatment (",
"      <a class=\"graphic graphic_table graphicRef78775 \" href=\"mobipreview.htm?17/51/18237\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60649 \" href=\"mobipreview.htm?41/40/42636\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical trial participation should be offered to all patients. In general, persons over the age of 65 are underrepresented in clinical trials, and prospective data to guide treatment in this growing population is a priority [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/5-8\">",
"       5-8",
"      </a>",
"      ]. In addition, few phase I trials have been conducted to establish the safety of newer antineoplastic agents in this potentially vulnerable population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444115996\">",
"    <span class=\"h2\">",
"     Organ function",
"    </span>",
"    &nbsp;&mdash;&nbsp;For older women who are candidates for chemotherapy, the evaluation of organ function is important because of the potential impact of organ dysfunction on tolerability of anti-cancer treatment, particularly as it relates to chemotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link&amp;anchor=H4#H4\">",
"       \"Systemic chemotherapy for cancer in elderly persons\", section on 'Liver'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link&amp;anchor=H5#H5\">",
"       \"Systemic chemotherapy for cancer in elderly persons\", section on 'Kidney'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link&amp;anchor=H7#H7\">",
"       \"Systemic chemotherapy for cancer in elderly persons\", section on 'Heart'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link&amp;anchor=H6#H6\">",
"       \"Systemic chemotherapy for cancer in elderly persons\", section on 'Bone marrow function'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENDOCRINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to hormone receptor-positive (and hormone receptor unknown) metastatic breast cancer (without life-threatening or rapidly progressive signs or symptoms) is similar in all postmenopausal women regardless of age. However, treatment should take into consideration the medical status and treatment preferences of the older patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/55/21370?source=see_link&amp;anchor=H1248533207#H1248533207\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\", section on 'Postmenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy is appropriate for older women with hormone receptor-negative breast cancer and for hormone receptor-positive disease that has progressed despite endocrine therapy, provided they are candidates for treatment. Chemotherapy should also be administered in the first-line setting if life-threatening or rapidly-progressive disease is present.",
"   </p>",
"   <p>",
"    Older women are less likely to receive chemotherapy despite data showing that age does not modify the survival benefit of chemotherapy for advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A model can be useful in predicting which patients should not receive chemotherapy because they are at increased risk of developing severe or fatal toxicity from chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef78775 \" href=\"mobipreview.htm?17/51/18237\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60649 \" href=\"mobipreview.htm?41/40/42636\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366328923\">",
"    <span class=\"h2\">",
"     Choice of agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest sequential single agent therapy rather than combination chemotherapy, particularly for frail or medically unfit older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. However, there is no optimal or preferred sequence of agents. A choice between them should be based on the patient&rsquo;s clinical status and careful consideration of the agents, their schedule of administration, and specific toxicities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=see_link\">",
"     \"Frailty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agents for which there is evidence of activity and toxicity specifically in older women are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709779451\">",
"    <span class=\"h3\">",
"     Anthracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthracyclines (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    ) are as effective in older women with metastatic breast cancer as they are in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, the risk of anthracycline-related cardiotoxicity may be higher in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/18\">",
"     18",
"    </a>",
"    ]. A study of 682 patients &ge;50 years old (seven percent of whom were 70 years or older) with metastatic breast cancer who received doxorubicin reported a similar cumulative probability of developing doxorubicin-induced heart failure; it was similar in women 50 to 64 years old and those older than 65 (6 and 9 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/17\">",
"     17",
"    </a>",
"    ]. The cumulative doses of doxorubicin administered to patients who developed congestive heart failure was also similar (410 and 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    respectively). Despite this, in a combined analysis of three different randomized trials (two involving patients with breast cancer, the other involving patients with lung cancer), patients &gt;65 years who received doxorubicin were at a greater risk for congestive heart failure compared to younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/18\">",
"     18",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    If an anthracycline is chosen, we suggest a weekly schedule or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    rather than another anthracycline because of the relatively lower risk of cardiotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/19\">",
"     19",
"    </a>",
"    ]. Two studies evaluated pegylated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    in anthracycline naive patients over age 65 or unsuitable for standard anthracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The overall response rate was approximately 30 percent. Toxicities included hematologic toxicity, anorexia, asthenia, and stomatitis.",
"   </p>",
"   <p>",
"    For older women who will receive an anthracycline, a baseline study for the cardiac left ventricular ejection fraction (LVEF) should be obtained prior to the initiation of treatment. In addition, symptoms should be carefully monitored and LVEF reassessed with onset of symptoms or periodically during therapy. Guidelines for anthracycline monitoring in adults using radionuclide ventriculography are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef58738 \" href=\"mobipreview.htm?42/21/43355\">",
"     table 3",
"    </a>",
"    ) and discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H25#H25\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444116407\">",
"    <span class=\"h4\">",
"     Dexrazoxane",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    for breast cancer who appear to be benefitting from treatment, coadministration of the cardioprotectant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    can reduce the risk of cardiotoxicity. Dexrazoxane is usually begun after a cumulative dose of 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of doxorubicin has been reached. There are no guidelines as to the use of dexrazoxane in women receiving epirubicin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H21#H21\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Dexrazoxane'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is an orally active prodrug of 5-fluorouracil that is absorbed intact through the intestinal wall and then converted to 5-FU in three sequential enzymatic reactions. Capecitabine is effective and well tolerated in older women with breast cancer as long as a lower initial dose (ie, 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily) is used. This is particularly true in the setting of mild to moderate renal impairment or hyperbilirubinemia. The activity of capecitabine was shown in a trial of 73 patients &ge;65 years with chemotherapy-naive metastatic breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/22\">",
"     22",
"    </a>",
"    ]. The overall response rate was 37 percent and treatment was well tolerated with serious (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    diarrhea, nausea, or fatigue occurring in less than 10 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vinorelbine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports demonstrate that single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    is active for older women with metastatic breast cancer, although neutropenia can be dose-limiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In the largest study, 56 women &ge;60 years old (57 percent ER-positive disease) were treated with vinorelbine at a dose of 30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as a weekly infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/24\">",
"     24",
"    </a>",
"    ]. The objective response rate was 38 percent, and there were two (4 percent) complete responses. At least one episode of grade 3 to 4 granulocytopenia occurred in 45 patients (80 percent), and six developed fever in the setting of neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taxanes are highly active agents in the treatment of metastatic breast cancer, even in heavily pretreated patients.",
"   </p>",
"   <p>",
"    Several studies have evaluated taxanes specifically in older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. In one randomized phase II study comparing weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    to weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    in older patients considered unfit for three-weekly taxane therapy, the main results were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of clinical benefit (response rate plus stable disease) was better with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (72 versus 54 percent, respectively). The difference was even more marked in patients age 70 and older in whom the rates of clinical benefits for paclitaxel and docetaxel were 67 and 44 percent, respectively.",
"     </li>",
"     <li>",
"      The time to progression on weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      was longer compared to weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (median, 21 versus 13 weeks, respectively).",
"     </li>",
"     <li>",
"      Weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      resulted in higher rates of anemia and neurotoxicity, while weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      resulted in higher rates of edema and fatigue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HER2-DIRECTED AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HER2-directed agents should be administered to older women with HER2-positive breast cancers. Although there are only limited data specifically looking at the toxicity of these agents in older women, data on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    (in the adjuvant setting) suggest that it is well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/33\">",
"     33",
"    </a>",
"    ]. Given the benefits of HER2-directed treatment for metastatic breast cancer, it should be a component of treatment of HER2-positive breast cancer regardless of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/55/21370?source=see_link&amp;anchor=H19266990#H19266990\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\", section on 'HER2-positive breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Granulocyte colony-stimulating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow tolerance is reduced in elderly patients and they may be at particular risk for febrile neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. We suggest the administration of prophylactic granulocyte colony stimulating factors (G-CSF) in older women if the risk of febrile neutropenia during chemotherapy is 20 percent or higher. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link&amp;anchor=H523774212#H523774212\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Primary prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic G-CSF in the management of elderly breast cancer patients was reviewed in a subanalysis of the Neulasta versus current practice neutropenia management (NeuCup) study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/37\">",
"     37",
"    </a>",
"    ]. In a subgroup analysis of 254 elderly patients (&ge;65 years) treated with chemotherapy with a moderately high (15 to 19 percent) or high (&ge;20 percent) febrile neutropenia risk, prophylactic G-CSF resulted in a significantly lower overall incidence of febrile neutropenia compared to standard practice (6 versus 24 percent). Prophylactic G-CSF was also associated with both decreased febrile neutropenia-related hospitalizations (5 versus 15 percent) and incidence of dose-reductions (&ge;10 versus &ge;15 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Erythropoiesis-stimulating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of erythropoietin stimulating agents (ESAs) in patients with nonhematologic malignancies appears to be restricted to those patients in whom the anemia is due to chemotherapy. In addition, there is some evidence that these agents may be harmful in patients with anemia not due to chemotherapy. The risks and benefits of ESAs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Osteoclast inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ) or other osteoclast inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    ) are routinely administered to patients with bone metastases, since they decrease the rate of bone complications (fractures, pain, and hypercalcemia) in women with bone metastases. However, older women should be aware of treatment-related toxicities, such as an increased risk of renal insufficiency and osteonecrosis of the jaw. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term administration is safe in elderly individuals, although patients should be monitored for renal insufficiency and hypocalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40903/abstract/38\">",
"     38",
"    </a>",
"    ]. Selection of therapy must be personalized taking into account the risk of toxicities, including hypocalcemia and renal dysfunction, as well as patient preferences, convenience, availability, and cost. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\", section on 'Choice of agent'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709780557\">",
"    <span class=\"h1\">",
"     PALLIATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all patients with metastatic breast cancer, palliative care should be a part of their interdisciplinary management. Palliative care focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients and their families facing serious illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with metastatic breast cancer are unlikely to be cured of their disease. However, with the availability of more treatment options, survival has improved over time. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Life expectancy, functional status, and organ function should be considered in the treatment of the older woman with metastatic breast cancer. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General treatment principles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link&amp;anchor=H7#H7\">",
"       \"General principles on the treatment of early stage and locally advanced breast cancer in older women\", section on 'Factors that affect treatment decisions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women over the age of 65 with hormone receptor-positive or hormone receptor unknown metastatic breast cancer, we recommend first-line endocrine therapy rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/55/21370?source=see_link&amp;anchor=H1248533207#H1248533207\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\", section on 'Postmenopausal women'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest chemotherapy as a first-line treatment for older women with metastatic breast cancer if disease is life-threatening or rapidly-progressive (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Chemotherapy is also appropriate for older women with hormone receptor-negative breast cancer and for hormone receptor-positive disease that has progressed on endocrine therapy, provided they are candidates for treatment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest sequential single agent therapy rather than combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women with HER2-positive disease, we recommend the addition of a HER2-directed agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). There is no optimal or preferred sequence of agents. A choice between them should be based on the patient&rsquo;s clinical status and careful consideration of the agents, their schedule of administration, and specific toxicities. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/55/21370?source=see_link&amp;anchor=H1056069971#H1056069971\">",
"       \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\", section on 'Postmenopausal women'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest primary prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) for older women with metastatic breast cancer if the risk of febrile neutropenia during chemotherapy is 20 percent or higher (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Granulocyte colony-stimulating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with metastatic breast cancer, palliative care should be a part of their interdisciplinary management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=see_link\">",
"       \"Palliative care: Benefits, services, and models of care\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/1\">",
"      Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/2\">",
"      Extermann M. Basic assessment of the older cancer patient. Curr Treat Options Oncol 2011; 12:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/3\">",
"      Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29:3457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/4\">",
"      Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118:3377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/5\">",
"      Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/6\">",
"      Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/7\">",
"      Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003; 21:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/8\">",
"      Kimmick GG, Peterson BL, Kornblith AB, et al. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol 2005; 23:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/9\">",
"      Hess D, Th&uuml;rlimann B, Pagani O, et al. Capecitabine and vinorelbine in elderly patients (&gt; or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 2004; 15:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/10\">",
"      Du X, Goodwin JS. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer 2001; 92:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/11\">",
"      Schneider M, Zuckerman IH, Onukwugha E, et al. Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: a population-based analysis. J Am Geriatr Soc 2011; 59:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/12\">",
"      Aapro M, Monfardini S, Jirillo A, Basso U. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev 2009; 35:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/13\">",
"      Hamberg P, Verweij J, Seynaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. Eur J Cancer 2007; 43:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/14\">",
"      Wilcken N, Dear R. Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. Eur J Cancer 2008; 44:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/15\">",
"      Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009; :CD003372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/16\">",
"      Ibrahim NK, Frye DK, Buzdar AU, et al. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 1996; 156:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/17\">",
"      Ibrahim NK, Hortobagyi GN, Ewer M, et al. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol 1999; 43:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/18\">",
"      Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97:2869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/19\">",
"      O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/20\">",
"      Coleman RE, Biganzoli L, Canney P, et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006; 42:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/21\">",
"      Biganzoli L, Coleman R, Minisini A, et al. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol 2007; 61:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/22\">",
"      Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/23\">",
"      Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997; 33:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/24\">",
"      Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999; 10:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/25\">",
"      Addeo R, Sgambato A, Cennamo G, et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 2010; 10:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/26\">",
"      Hainsworth JD, Burris HA 3rd, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19:3500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/27\">",
"      D'hondt R, Paridaens R, Wildiers H, et al. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 2004; 15:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/28\">",
"      ten Tije AJ, Smorenburg CH, Seynaeve C, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004; 40:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/29\">",
"      Del Mastro L, Perrone F, Repetto L, et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005; 16:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/30\">",
"      Lichtman SM, Hurria A, Cirrincione CT, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2012; 23:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/31\">",
"      Hurria A, Fleming MT, Baker SD, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006; 12:6100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/32\">",
"      Beuselinck B, Wildiers H, Wynendaele W, et al. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology. Crit Rev Oncol Hematol 2010; 75:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/33\">",
"      Sawaki M, Mukai H, Tokudome N, et al. Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. Breast Cancer 2012; 19:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/34\">",
"      Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000; 18:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/35\">",
"      Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003; 1:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/36\">",
"      Balducci L, Lyman GH. Patients aged &gt; or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 2001; 19:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/37\">",
"      Aapro M, Schwenkglenks M, Lyman GH, et al. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 2010; 74:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40903/abstract/38\">",
"      Tralongo P, Repetto L, Di Mari A, et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 2004; 67:112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 761 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40903=[""].join("\n");
var outline_f39_60_40903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444115996\">",
"      Organ function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENDOCRINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H366328923\">",
"      Choice of agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709779451\">",
"      - Anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H444116407\">",
"      Dexrazoxane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vinorelbine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Taxanes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HER2-DIRECTED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Granulocyte colony-stimulating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Erythropoiesis-stimulating agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Osteoclast inhibition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H709780557\">",
"      PALLIATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/761\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/761|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/51/18237\" title=\"table 1\">",
"      Model for predicting chemotherapy toxicity in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/40/42636\" title=\"table 2\">",
"      Risk score versus physician-rated KPS chemo toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/21/43355\" title=\"table 3\">",
"      Doxorubicin cardiac monitoring",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=related_link\">",
"      Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19464?source=related_link\">",
"      Management of brain metastases in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_60_40904="Disciform erythrasma";
var content_f39_60_40904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disciform erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40904=[""].join("\n");
var outline_f39_60_40904=null;
var title_f39_60_40905="Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis";
var content_f39_60_40905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/60/40905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40905/contributors\">",
"     Joseph Merola, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/60/40905/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40905/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/60/40905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40905/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/60/40905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30497559\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sweet syndrome (acute febrile neutrophilic dermatosis) is an uncommon inflammatory disorder characterized by the abrupt appearance of painful, edematous, and erythematous papules, plaques, or nodules on the skin. Fever and leukocytosis frequently accompany the cutaneous lesions. In addition, involvement of the eyes, musculoskeletal system, and internal organs may occur.",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, and diagnosis of Sweet syndrome will be discussed here. Information on the treatment and prognosis of Sweet syndrome and an overview of other neutrophilic dermatoses are available separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/10/21671?source=see_link\">",
"     \"Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link\">",
"     \"Neutrophilic dermatoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1950250\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sweet syndrome was first described by Dr. Robert Douglas Sweet in 1964, who documented the development of an acute inflammatory skin eruption with fever and leukocytosis in eight women, several of whom had preceding upper respiratory or gastrointestinal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/1\">",
"     1",
"    </a>",
"    ]. Since then, Sweet syndrome has been observed in association with a broad range of disorders. As a result, some authors divide Sweet syndrome into three subtypes based upon etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classical Sweet syndrome",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Malignancy-associated Sweet syndrome",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Drug-induced Sweet syndrome",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1950288\">",
"    <span class=\"h2\">",
"     Classical Sweet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical Sweet syndrome (also referred to as idiopathic Sweet syndrome) constitutes the majority of cases of Sweet syndrome and is defined as Sweet syndrome that meets the established diagnostic criteria and is not associated with malignancy or drug exposure (",
"    <a class=\"graphic graphic_table graphicRef85940 \" href=\"mobipreview.htm?14/37/14940\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2\">",
"     2",
"    </a>",
"    ]. Classical Sweet syndrome may occur in the setting of a variety of medical conditions. The conditions that are most frequently associated with classical Sweet syndrome are listed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Infections",
"      </strong>",
"      (particularly upper respiratory tract and gastrointestinal infections; Sweet syndrome usually develops one to three weeks after infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/6\">",
"       6",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      <strong>",
"       Inflammatory bowel disease",
"      </strong>",
"      (Crohn&rsquo;s disease and ulcerative colitis)",
"     </li>",
"     <li>",
"      <strong>",
"       Pregnancy",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less frequent and less definitive associations exist with other infections (eg, human immunodeficiency virus [HIV], tuberculosis, chlamydia, viral hepatitis), primary immunodeficiencies, and autoimmune conditions (eg, Beh&ccedil;et&rsquo;s disease, relapsing polychondritis, rheumatoid arthritis, sarcoidosis, autoimmune thyroid disease, connective tissue disorders including systemic lupus erythematosus and dermatomyositis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Further studies are necessary to determine the strength of the relationships between Sweet syndrome and these diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1950295\">",
"    <span class=\"h2\">",
"     Malignancy-associated Sweet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy-associated Sweet syndrome accounts for a significant portion of cases of Sweet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. A 1993 review of several retrospective series found that 25 of 118 patients with Sweet syndrome (21 percent) had a hematologic or solid tumor malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/8\">",
"     8",
"    </a>",
"    ]. In children, malignancy-associated Sweet syndrome appears to primarily occur in children over the age of three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/9\">",
"     9",
"    </a>",
"    ]. Rare cases of malignancy-associated Sweet syndrome have been reported in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sweet syndrome may precede, follow, or appear concurrently with a malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/8,13-44\">",
"     8,13-44",
"    </a>",
"    ]. In patients with previous histories of cancer, the development of Sweet syndrome may portend disease recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sweet syndrome is more likely to occur in association with hematologic malignancies than solid tumor cancers. In a 1998 review of 79 patients with malignancies and Sweet syndrome, 69 (87 percent) had hematologic malignancies and 12 had solid tumors (15 percent), including two patients who had both acute myelogenous leukemia (AML) and prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/45\">",
"     45",
"    </a>",
"    ]. AML is the malignancy most frequently associated with Sweet syndrome. In the review, AML accounted for 42 percent of the hematologic malignancies and myeloproliferative disorders comprised the second most common category of malignancy (22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/45\">",
"     45",
"    </a>",
"    ]. Among solid tumors, carcinomas of the genitourinary organs, breast, and gastrointestinal tract are most frequently linked with Sweet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/8,46\">",
"     8,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1950361\">",
"    <span class=\"h2\">",
"     Drug-induced Sweet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple drugs may contribute to Sweet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/47-56\">",
"     47-56",
"    </a>",
"    ]. A list of drugs that have been associated with Sweet syndrome is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef85942 \" href=\"mobipreview.htm?22/58/23469\">",
"     table 2",
"    </a>",
"    ). Granulocyte-colony stimulating factor (G-CSF) is the most widely reported contributory medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sweet syndrome usually develops about two weeks after drug exposure in patients who lack a prior history of exposure to the inciting drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/57\">",
"     57",
"    </a>",
"    ]. Recurrence of the syndrome usually develops after reexposure to the inciting drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30497566\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although individuals between the ages of 30 and 60 most frequently develop Sweet syndrome, infants, children, and older adults may also be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. The mean age for reported pediatric cases is slightly over five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sex distribution varies with the subtype of Sweet syndrome and patient age. In classical Sweet syndrome, 80 percent of patients are women, whereas the proportion of women is lower in other clinical variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2\">",
"     2",
"    </a>",
"    ]. In Sweet syndrome associated with drugs, solid tumors, and hematologic malignancies, the percentage of patients who are women is estimated to be 70, 60, and 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2\">",
"     2",
"    </a>",
"    ]. The female predominance in Sweet syndrome does not appear to apply to children. In a systematic review that included 66 reports of children with Sweet syndrome, the disorder was twice as likely to occur in males among children under the age of three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/9\">",
"     9",
"    </a>",
"    ]. In children over the age of three, the sex distribution was equal.",
"   </p>",
"   <p>",
"    There is no obvious racial predilection in Sweet syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30497573\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of Sweet syndrome is not well understood. Factors theorized to contribute to the development of this disorder include hypersensitivity reactions, cytokine dysregulation, and genetic susceptibility.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hypersensitivity reaction",
"      </strong>",
"      &ndash; An immune reaction to bacterial, viral, tumor, or other antigens could influence the development of Sweet syndrome through stimulating the production of cytokines that promote neutrophil activation and infiltration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/58\">",
"       58",
"      </a>",
"      ]. The positive response to systemic glucocorticoids and reports of improvement in Sweet syndrome following treatment of bacterial infections or malignancies offer some support to this theory [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/58-60\">",
"       58-60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cytokine dysregulation",
"      </strong>",
"      &ndash; Certain cytokines and chemokines may contribute to the initiation and propagation of the inflammatory response in Sweet syndrome. A role for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) is compelling, since G-CSF increases circulating neutrophils and exogenous G-CSF is a common cause of drug-induced Sweet syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/50\">",
"       50",
"      </a>",
"      ]. Moreover, higher serum levels of G-CSF have been detected in patients with active Sweet syndrome than in patients with inactive disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/61\">",
"       61",
"      </a>",
"      ]. Increased production of G-CSF by tumor cells has also been proposed as a potential factor in malignancy-associated disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2,62\">",
"       2,62",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukins (eg, IL-1, IL-3, IL-6, and IL-8) are postulated to play roles in Sweet syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/63-66\">",
"       63-66",
"      </a>",
"      ]. In a study of eight patients with Sweet syndrome, serum levels of Th1 cytokines, including IL-1&alpha;, IL-1&beta;, IL-2, and interferon-gamma were elevated, whereas levels of IL-4, a Th2 cytokine remained normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Genetic susceptibility",
"      </strong>",
"      &ndash; Abnormalities in chromosome 3q have been reported in association with Sweet syndrome in a few patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/31,68-70\">",
"       31,68-70",
"      </a>",
"      ]. HLA-B54 has been linked to Sweet syndrome in Japanese patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/71,72\">",
"       71,72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antibodies to neutrophilic cytoplasmic antigens have been detected in some patients with Sweet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/70,73\">",
"     70,73",
"    </a>",
"    ]. However, a pathogenic role for these antibodies has not been established. Further study is necessary to clarify the mechanisms that lead to the development of Sweet syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30497594\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the abrupt onset of the painful inflammatory papules, plaques, and nodules that characterize Sweet syndrome, additional clinical features may develop. An overview of the mucocutaneous and extracutaneous manifestations of Sweet syndrome is provided below. The differences in the clinical and laboratory features of the subtypes of Sweet syndrome are provided in a table (",
"    <a class=\"graphic graphic_table graphicRef85941 \" href=\"mobipreview.htm?3/40/3726\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1955675\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous lesions of Sweet syndrome typically present as tender, edematous, and inflamed papules, plaques, and nodules (",
"    <a class=\"graphic graphic_picture graphicRef74393 graphicRef85644 graphicRef85645 graphicRef85646 graphicRef79243 graphicRef85647 \" href=\"mobipreview.htm?42/46/43754\">",
"     picture 1A-F",
"    </a>",
"    ). Lesions are usually several millimeters to several centimeters in diameter and exhibit a brightly erythematous or violaceous color.",
"   </p>",
"   <p>",
"    The inflammatory papules and plaques often exhibit a mamillated surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/74\">",
"     74",
"    </a>",
"    ]. Significant superficial dermal edema leading to a pseudovesicular quality is common. Pustules may also be present. In some cases, the skin lesions develop a central yellowish hue resulting in a targetoid appearance.",
"   </p>",
"   <p>",
"    The distribution of the cutaneous eruption is often asymmetrical. Overall, the head, neck, and upper extremities are favored sites for involvement. Skin lesions may also occur on the lower extremities in drug-induced or malignancy-associated disease, but are infrequently found on the lower extremities in classical Sweet syndrome (",
"    <a class=\"graphic graphic_table graphicRef85941 \" href=\"mobipreview.htm?3/40/3726\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients often describe the pain associated with cutaneous lesions in Sweet syndrome as tenderness or a burning sensation. Pruritus usually does not occur.",
"   </p>",
"   <p>",
"    Less common presentations of Sweet syndrome include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bullous Sweet syndrome",
"      </strong>",
"      &ndash; Bullous Sweet syndrome is an uncommon presentation of Sweet syndrome in which vesicles and flaccid bullae overly erythematous to violaceous plaques (",
"      <a class=\"graphic graphic_picture graphicRef62314 graphicRef50526 \" href=\"mobipreview.htm?21/7/21625\">",
"       picture 2A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/58\">",
"       58",
"      </a>",
"      ]. Ulceration resembling pyoderma gangrenosum may occur in bullous Sweet syndrome; this manifestation most commonly occurs in the setting of hematologic malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/28,74\">",
"       28,74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Subcutaneous Sweet syndrome",
"      </strong>",
"      &ndash; In subcutaneous Sweet syndrome, the site of neutrophilic infiltration is in the subcutaneous fat, rather than the dermis (see",
"      <a class=\"local\" href=\"#H2457599\">",
"       'Pathology findings'",
"      </a>",
"      below). This results in the development of erythematous nodules with minimal superficial change. The nodules are usually 2 to 3 cm in diameter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/75\">",
"       75",
"      </a>",
"      ], and the extremities are common sites of involvement. Subcutaneous Sweet syndrome can closely resemble erythema nodosum, particularly when it involves the lower legs (",
"      <a class=\"graphic graphic_picture graphicRef63142 \" href=\"mobipreview.htm?40/52/41806\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Neutrophilic dermatosis of the dorsal hands",
"      </strong>",
"      &ndash; Neutrophilic dermatosis of the dorsal hands (also known as pustular vasculitis of the dorsal hands) is a localized disorder that may be on a continuum with Sweet syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/77\">",
"       77",
"      </a>",
"      ]. Affected patients develop inflammatory and pustular plaques on the dorsal surfaces of the hands (",
"      <a class=\"graphic graphic_picture graphicRef69295 \" href=\"mobipreview.htm?13/26/13730\">",
"       picture 4",
"      </a>",
"      ). Neutrophilic dermatosis of the dorsal hands is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link&amp;anchor=H30#H30\">",
"       \"Neutrophilic dermatoses\", section on 'Neutrophilic dermatosis of the dorsal hands'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, three patients with Sweet syndrome resembling necrotizing fasciitis (necrotizing Sweet syndrome) have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/78\">",
"     78",
"    </a>",
"    ]. These immunosuppressed patients developed fever accompanied by expanding erythematous to violaceous plaques. Underlying risk factors for Sweet syndrome (exposure to G-CSF, malignancy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HIV infection) were present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link&amp;anchor=H8#H8\">",
"     \"Necrotizing soft tissue infections\", section on 'Necrotizing fasciitis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Large cellulitis-like plaques may be another rare clinical presentation of Sweet syndrome. The term &ldquo;giant cellulitis-like Sweet syndrome&rdquo; was used to refer to the development of large infiltrated inflammatory plaques and bullae in three patients who met diagnostic criteria for Sweet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H705447\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The phenomenon of",
"    <strong>",
"     pathergy",
"    </strong>",
"    (lesion development at sites of cutaneous injury) may occur in patients with Sweet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/9\">",
"     9",
"    </a>",
"    ]. Even minor trauma, such as that obtained with a needle stick, may result in the development of skin lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704799\">",
"    <span class=\"h2\">",
"     Oral cavity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral involvement is uncommon in classical Sweet syndrome. However, approximately 12 percent of patients with Sweet syndrome related to hematologic malignancies develop oral ulcers as a disease manifestation, particularly on the buccal mucosa or tongue (",
"    <a class=\"graphic graphic_table graphicRef85941 \" href=\"mobipreview.htm?3/40/3726\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2\">",
"     2",
"    </a>",
"    ]. Additional reported oral findings include bullae, vesicles, gingival hyperplasia, necrotizing ulcerative periodontitis, nodules, papules, pustules, and tongue swelling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2,80\">",
"     2,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704827\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The name &ldquo;acute febrile neutrophilic dermatosis&rdquo; reflects the frequent presence of fever &gt;38&deg;C in Sweet syndrome. Patients with drug-induced Sweet syndrome are almost always febrile, but fever may spare 10 to 20 percent of patients with classical or malignancy-associated disease (",
"    <a class=\"graphic graphic_table graphicRef85941 \" href=\"mobipreview.htm?3/40/3726\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2\">",
"     2",
"    </a>",
"    ]. Arthralgias, malaise, headache, and myalgias are additional symptoms that frequently occur in Sweet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/6,74\">",
"     6,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30497601\">",
"    <span class=\"h2\">",
"     Extracutaneous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilic infiltration of other organ systems, such as the eye, muscles, lung, bone, liver, spleen, heart, kidneys, central nervous system, and gastrointestinal system may occur in Sweet syndrome, resulting in signs or symptoms specific to the extracutaneous site of inflammation. Ocular inflammation is a common extracutaneous manifestation; ocular involvement occurs in 17 to 72 percent of patients with the classical variant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2\">",
"     2",
"    </a>",
"    ]. Examples of ocular manifestations include conjunctivitis, episcleritis, scleritis, limbal nodules, peripheral ulcerative keratitis, iritis, glaucoma, dacryoadenitis, and choroiditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The musculoskeletal system is another frequent site of extracutaneous involvement, manifesting as arthralgias, arthritis, and myalgias.",
"   </p>",
"   <p>",
"    Examples of uncommon extracutaneous manifestations of Sweet syndrome include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/6,74\">",
"     6,74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Central nervous system",
"      </strong>",
"      &ndash; encephalitis, aseptic meningitis",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiovascular system",
"      </strong>",
"      &ndash; myocarditis, aortitis and aortic stenosis, coronary artery occlusion",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary system",
"      </strong>",
"      &ndash; neutrophilic alveolitis, pleural effusions, airway obstruction",
"     </li>",
"     <li>",
"      <strong>",
"       Liver",
"      </strong>",
"      &ndash; hepatitis, hepatomegaly",
"     </li>",
"     <li>",
"      <strong>",
"       Intestines",
"      </strong>",
"      &ndash; neutrophilic inflammation of intestines",
"     </li>",
"     <li>",
"      <strong>",
"       Spleen",
"      </strong>",
"      &ndash; splenomegaly",
"     </li>",
"     <li>",
"      <strong>",
"       Kidneys",
"      </strong>",
"      &ndash; mesangial glomerulonephritis, hematuria, proteinuria",
"     </li>",
"     <li>",
"      <strong>",
"       Bone",
"      </strong>",
"      &ndash; sterile osteomyelitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of systemic inflammatory response syndrome (SIRS) in the setting of Sweet syndrome has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/16,83-85\">",
"     16,83-85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691464001\">",
"    <span class=\"h2\">",
"     Associated laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral leukocytosis with neutrophilia is the most common laboratory abnormality in patients with Sweet syndrome. Neutrophilia is present in the vast majority of patients with classical Sweet syndrome, and in a significant proportion of patients with malignancy-associated and drug-induced disease (",
"    <a class=\"graphic graphic_table graphicRef85941 \" href=\"mobipreview.htm?3/40/3726\">",
"     table 3",
"    </a>",
"    ). Nonspecific inflammatory markers such as the erythrocyte sedimentation rate and C-reactive protein level are also frequently elevated in patients with Sweet syndrome.",
"   </p>",
"   <p>",
"    Anemia and platelet abnormalities are commonly seen in Sweet syndrome related to malignancy or drugs, but are infrequently detected in patients with classical Sweet syndrome (",
"    <a class=\"graphic graphic_table graphicRef85941 \" href=\"mobipreview.htm?3/40/3726\">",
"     table 3",
"    </a>",
"    ). Abnormalities on the complete metabolic panel and urinalysis may indicate hepatic or renal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1955716\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Sweet syndrome is based upon the recognition of consistent clinical and laboratory findings as well as the exclusion of disorders that may present with similar clinical features. A rapid and dramatic response to systemic glucocorticoid therapy also supports the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705447\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A revised set of diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/86\">",
"     86",
"    </a>",
"    ] based upon criteria outlined in 1986 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/48\">",
"     48",
"    </a>",
"    ] are widely used for the diagnosis of Sweet syndrome (",
"    <a class=\"graphic graphic_table graphicRef85940 \" href=\"mobipreview.htm?14/37/14940\">",
"     table 1",
"    </a>",
"    ). Both major criteria and two of four minor criteria are required to establish a diagnosis of classical or malignancy-associated Sweet syndrome.",
"   </p>",
"   <p>",
"    <strong>",
"     Major criteria:",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abrupt onset of painful erythematous plaques or nodules",
"     </li>",
"     <li>",
"      Histopathologic evidence of a dense neutrophilic infiltrate without evidence of leukocytoclastic vasculitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Minor criteria:",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pyrexia &gt;38&deg;C",
"     </li>",
"     <li>",
"      Association with underlying hematologic or visceral malignancy, inflammatory disease or pregnancy, OR preceded by upper respiratory infection, gastrointestinal infection, or vaccination",
"     </li>",
"     <li>",
"      Excellent response to treatment with systemic glucocorticoids or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"     </li>",
"     <li>",
"      Abnormal laboratory values at presentation (three of four of the following: erythrocyte sedimentation rate &gt;20",
"      <span class=\"nowrap\">",
"       mm/hr,",
"      </span>",
"      positive C-reactive protein, &gt;8,000 leukocytes, &gt;70 percent neutrophils)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate set of criteria have been proposed for drug-induced Sweet syndrome (",
"    <a class=\"graphic graphic_table graphicRef85940 \" href=\"mobipreview.htm?14/37/14940\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705454\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical assessment of the patient offers valuable clues for diagnosis. The history may reveal a rapid onset of skin lesions and the presence of associated symptoms (eg, painful skin lesions, fever, malaise), findings that are compatible with Sweet syndrome. In addition, the knowledge that a patient has a condition known to occur in association with Sweet syndrome (eg, recent infection, malignancy, pregnancy, or inflammatory bowel disease) raises clinical suspicion for the diagnosis. (See",
"    <a class=\"local\" href=\"#H30497594\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1950250\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A complete physical examination that includes surveillance of the entire skin surface should be performed. This aids in determining whether the morphology and distribution of skin lesions is consistent with Sweet syndrome and allows for an assessment of the extent of cutaneous disease as well as an evaluation for signs of extracutaneous involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12627044\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients in whom the clinical findings suggest the possibility of Sweet syndrome, a skin biopsy and select laboratory tests are indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2457524\">",
"    <span class=\"h3\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of consistent histological findings is a major diagnostic criterion for Sweet syndrome (",
"    <a class=\"graphic graphic_table graphicRef85940 \" href=\"mobipreview.htm?14/37/14940\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H705447\">",
"     'Diagnostic criteria'",
"    </a>",
"    above). Thus, a skin biopsy should be performed whenever feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12627162\">",
"    <span class=\"h4\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with inflammatory papules or plaques, a 4 mm punch biopsy is usually sufficient for obtaining a tissue specimen for histological examination. Because infection may closely resemble Sweet syndrome, microbial pathology stains should be performed. In addition, we obtain a second 4 mm punch biopsy for bacterial, fungal, and mycobacterial cultures. If pustules are present, a swab specimen can also be sent for culture.",
"   </p>",
"   <p>",
"    In patients with nodules suggestive of subcutaneous Sweet syndrome (a variant in which the pathologic process is primarily located in the subcutaneous fat), an excisional biopsy is preferred because it provides a more generous sample of the subcutaneous fat, which may facilitate the interpretation of the histological findings. As above, a portion of the tissue specimen should be sent for microbial cultures. (See",
"    <a class=\"local\" href=\"#H2457599\">",
"     'Pathology findings'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link\">",
"     \"Skin biopsy techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=see_link&amp;anchor=H15212571#H15212571\">",
"     \"Panniculitis: Recognition and diagnosis\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2457599\">",
"    <span class=\"h4\">",
"     Pathology findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic histologic features of Sweet syndrome include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/87\">",
"     87",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prominent edema in the superficial dermis",
"     </li>",
"     <li>",
"      Dense infiltrate of neutrophils in the upper and mid-dermis with sparing of the epidermis (",
"      <a class=\"graphic graphic_picture graphicRef66680 \" href=\"mobipreview.htm?33/51/34613\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Leukocytoclasis",
"     </li>",
"     <li>",
"      Endothelial swelling",
"     </li>",
"     <li>",
"      Absence of vasculitis (see below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A few eosinophils may also be present. Older lesions may exhibit small numbers of lymphocytes or macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the absence of vasculitis is considered a characteristic feature of Sweet syndrome, the identification of vasculitis in a biopsy specimen does not rule out the diagnosis. In a retrospective study of skin biopsies from 21 patients with Sweet syndrome, vasculitis was identified in specimens from 6 patients (29 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/88\">",
"     88",
"    </a>",
"    ]. The vasculitis seen in Sweet syndrome may be a secondary phenomenon related to the release of noxious products from neutrophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathological variants of Sweet syndrome include subcutaneous Sweet syndrome and histiocytoid Sweet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/89-93\">",
"     89-93",
"    </a>",
"    ]. Subcutaneous Sweet syndrome is characterized by a dense neutrophilic infiltrate in the subcutaneous tissue. Although lobular inflammation is usually most prominent, both septa and lobules may be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/75\">",
"     75",
"    </a>",
"    ]. In histiocytoid Sweet syndrome, the dermal inflammatory infiltrate is primarily composed of histiocyte-like immature myeloid cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic differential diagnosis of Sweet syndrome is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef85943 \" href=\"mobipreview.htm?30/19/31036\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705462\">",
"    <span class=\"h3\">",
"     Serologic and other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation is useful for identifying findings consistent with Sweet syndrome (eg, leukocytosis) and signs of associated diseases or extracutaneous involvement. Our routine laboratory work-up for patients with suspected Sweet syndrome includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with platelets and differential",
"     </li>",
"     <li>",
"      Complete metabolic panel",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate or C-reactive protein",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional laboratory studies are ordered based upon suspicion for specific sites of extracutaneous disease and associated underlying disorders. For example, patients with pulmonary symptoms, pleuritis, or hypoxia should have a chest radiograph to look for signs of pulmonary involvement. Examples of additional investigations for an underlying disorder include searches for evidence of recent streptococcal infection or an occult malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H565690\">",
"    <span class=\"h2\">",
"     Evaluation for malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy testing should only be considered in the setting of reasonable clinical suspicion for an underlying malignancy (eg, constitutional symptoms such as weight loss) and the absence of another explanation for a Sweet syndrome diagnosis (ie, pregnancy, drug exposure, recent infection, inflammatory bowel disease, rheumatoid arthritis, etc.). The screening for malignancy should begin with age-appropriate cancer screening guidelines. Some experts have proposed a work-up based upon the most common malignancies reported in association with Sweet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/8\">",
"     8",
"    </a>",
"    ]. This includes a physical examination that incorporates thyroid and lymph node examinations, as well as breast, cervical, uterine, and ovarian cancer screening in women and prostate and testicular examinations in men. Additional tests considered by these authors include a carcinoembryonic antigen level, colon cancer screening, and a chest radiograph. Other authors have suggested the use of chest, abdomen, and pelvis CT imaging or PET-CT imaging to evaluate for malignancy in patients with paraneoplastic conditions and reasonable suspicion for a malignancy of unknown source; this is similar to the literature for malignancy work-up of dermatomyositis, which is largely driven by expert opinion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40905/abstract/95-97\">",
"     95-97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H705609\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is one of the most important disorders to consider in the patient with clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histological findings suggestive of Sweet syndrome. As in Sweet syndrome, fever, leukocytosis, and cutaneous lesions characterized by neutrophil-dense infiltrates may occur in bacterial sepsis. In addition, the lesions of Sweet syndrome can resemble local bacterial, fungal, or atypical mycobacterial infections.",
"   </p>",
"   <p>",
"    The clinical differential diagnosis of Sweet syndrome is dependent upon lesion morphology. Data obtained from the clinical history, physical examination, pathology findings, and microbial studies are useful for distinguishing between Sweet syndrome and other conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Erythematous, edematous plaques:",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cutaneous infection (bacterial, fungal, and mycobacterial)",
"     </li>",
"     <li>",
"      Urticaria and urticarial vasculitis",
"     </li>",
"     <li>",
"      Other neutrophilic dermatoses (eg, pyoderma gangrenosum, neutrophilic eccrine hidradenitis, Beh&ccedil;et's disease, cutaneous metastatic Crohn&rsquo;s disease)",
"     </li>",
"     <li>",
"      Drug eruptions",
"     </li>",
"     <li>",
"      Halogenoderma (eg, bromoderma, iododerma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nodules (including subcutaneous Sweet syndrome):",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cutaneous infection (eg, deep fungal infection, Majocchi&rsquo;s granuloma, atypical mycobacterial infection)",
"     </li>",
"     <li>",
"      Malignancy (eg, lymphoma cutis, leukemia cutis, metastatic carcinoma)",
"     </li>",
"     <li>",
"      Subcutaneous sarcoidosis",
"     </li>",
"     <li>",
"      Vasculitis (particularly medium-vessel vasculitis such as cutaneous polyarteritis nodosa)",
"     </li>",
"     <li>",
"      Erythema nodosum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bullous lesions:",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bullous pyoderma gangrenosum",
"     </li>",
"     <li>",
"      Bullous leukocytoclastic vasculitis",
"     </li>",
"     <li>",
"      Autoimmune bullous diseases (eg, bullous pemphigoid, bullous systemic lupus erythematosus, inflammatory epidermolysis bullosa acquisita, linear IgA bullous dermatosis)",
"     </li>",
"     <li>",
"      Infection with bullous and hemorrhagic or necrotic changes (eg, bullous cellulitis, vessel invasive infections such as aspergillosis, ecthyma gangrenosum).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histopathologic differential diagnosis of Sweet syndrome is reviewed in a table (",
"    <a class=\"graphic graphic_table graphicRef85943 \" href=\"mobipreview.htm?30/19/31036\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3380028\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sweet syndrome (acute febrile neutrophilic dermatosis) is an inflammatory disorder characterized by the presence of inflammatory papules, plaques, or nodules on the skin, systemic symptoms, and neutrophilic infiltration of the skin. Sweet syndrome is often divided into three categories based on etiology: classical Sweet syndrome, malignancy-associated Sweet syndrome, and drug-induced Sweet syndrome (",
"      <a class=\"graphic graphic_table graphicRef85941 \" href=\"mobipreview.htm?3/40/3726\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1950250\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classical Sweet syndrome includes cases of Sweet syndrome that are not associated with malignancy or drug exposure. The most common causes of malignancy-associated Sweet syndrome and drug-induced Sweet syndrome are acute myelogenous leukemia and granulocyte-colony stimulating factor (G-CSF), respectively. (See",
"      <a class=\"local\" href=\"#H1950250\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cutaneous lesions of Sweet syndrome are typically painful, erythematous to violaceous papules and plaques. Pseudovesiculation and pustule formation are often present. Bullous Sweet syndrome and subcutaneous Sweet syndrome are less common manifestations. (See",
"      <a class=\"local\" href=\"#H1955675\">",
"       'Cutaneous'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fever, malaise, joint pain, and muscle pain often accompany the cutaneous lesions. Involvement of internal organs may also occur. Leukocytosis and elevations in the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level are common laboratory findings. (See",
"      <a class=\"local\" href=\"#H704827\">",
"       'Associated symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30497601\">",
"       'Extracutaneous disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H691464001\">",
"       'Associated laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A diagnosis of Sweet syndrome is made based upon both clinical and laboratory findings (",
"      <a class=\"graphic graphic_table graphicRef85940 \" href=\"mobipreview.htm?14/37/14940\">",
"       table 1",
"      </a>",
"      ). Biopsies characteristically demonstrate a dense neutrophilic infiltrate in the dermis without vasculitis. (See",
"      <a class=\"local\" href=\"#H1955716\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/1\">",
"      SWEET RD. AN ACUTE FEBRILE NEUTROPHILIC DERMATOSIS. Br J Dermatol 1964; 76:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/2\">",
"      Cohen PR. Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/3\">",
"      Lallas A, Tzellos TG, Papageorgiou M, Mandekou-Lefaki I. Sweet's syndrome associated with upper respiratory tract streptococcal infection: \"wait-and-see\" strategy or anecdotal use of corticosteroids? Hippokratia 2011; 15:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/4\">",
"      Ytting H, Vind I, Bang D, Munkholm P. Sweet's syndrome--an extraintestinal manifestation in inflammatory bowel disease. Digestion 2005; 72:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/5\">",
"      Satra K, Zalka A, Cohen PR, Grossman ME. Sweet's syndrome and pregnancy. J Am Acad Dermatol 1994; 30:297.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen PR, Hongsmann H, Kurzrock R. Acute febrile neutrophilic dermatosis (Sweet syndrome). In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al..  (Eds), McGraw Hill, 2012. Vol 1, p.362.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/7\">",
"      Gray PE, Bock V, Ziegler DS, Wargon O. Neonatal Sweet syndrome: a potential marker of serious systemic illness. Pediatrics 2012; 129:e1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/8\">",
"      Cohen PR, Kurzrock R. Sweet's syndrome and cancer. Clin Dermatol 1993; 11:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/9\">",
"      Halpern J, Salim A. Pediatric sweet syndrome: case report and literature review. Pediatr Dermatol 2009; 26:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/10\">",
"      Bourke JF, Keohane S, Long CC, et al. Sweet's syndrome and malignancy in the U.K. Br J Dermatol 1997; 137:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/11\">",
"      Uihlein LC, Brandling-Bennett HA, Lio PA, Liang MG. Sweet syndrome in children. Pediatr Dermatol 2012; 29:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/12\">",
"      Krilov LR, Jacobson M, Shende A. Acute febrile neutrophilic dermatosis (Sweet's syndrome) presenting as facial cellulitis in a child with juvenile chronic myelogenous leukemia. Pediatr Infect Dis J 1987; 6:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/13\">",
"      Miranda CV, Filgueiras Fde M, Obadia DL, et al. Sweet's Syndrome associated with Hodgkin's disease: case report. An Bras Dermatol 2011; 86:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/14\">",
"      Wawrzycki B, Chodorowska G, Pietrzak A, et al. Recurrent skin eruption in patient with chronic lymphocytic leukemia and lymphocytic infiltrates of the dermis resembling Sweet's syndrome. G Ital Dermatol Venereol 2011; 146:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/15\">",
"      Ravaglia C, Poletti G, Gurioli C, et al. Sweet's syndrome associated with myelogenous leukemia and pulmonary involvement. Monaldi Arch Chest Dis 2011; 75:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/16\">",
"      Shugarman IL, Schmit JM, Sbicca JA, Wirk B. Easily missed extracutaneous manifestation of malignancy-associated Sweet's syndrome: systemic inflammatory response syndrome. J Clin Oncol 2011; 29:e702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/17\">",
"      Kato T, Kawana S, Takezaki S, et al. Case of Sweet's syndrome with extensive necrosis and ulcers accompanied by myelodysplastic syndrome. J Nippon Med Sch 2008; 75:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/18\">",
"      Glendenning J, Khoo V. Sweet's syndrome in prostate cancer. Prostate Cancer Prostatic Dis 2008; 11:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/19\">",
"      Awan F, Hamadani M, Devine S. Paraneoplastic Sweet's syndrome and the pathergy phenomenon. Ann Hematol 2007; 86:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/20\">",
"      Culp L, Crowder S, Hatch S. A rare association of Sweet's syndrome with cervical cancer. Gynecol Oncol 2004; 95:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/21\">",
"      Dereure O, Ebrard-Charra S, Guillon F, et al. Sweet's syndrome associated with pheochromocytoma. Dermatology 2004; 208:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/22\">",
"      Liu D, Seiter K, Mathews T, et al. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. Leuk Res 2004; 28 Suppl 1:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/23\">",
"      Gille J, Spieth K, Kaufmann R. Sweet's syndrome as initial presentation of diffuse large B-cell lymphoma. J Am Acad Dermatol 2002; 46:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/24\">",
"      Zappasodi P, Corso A, del Forno C. Sweet's syndrome and myelodysplasia: two entities with a common pathogenetic mechanism? A case report. Haematologica 2000; 85:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/25\">",
"      Suvajdzi�� N, Dimci�� Z, Cvijeti�� O, Colovi�� M. Sweet's syndrome associated with Hodgkin's disease. Haematologia (Budap) 1998; 29:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/26\">",
"      Aubin F, Dufour MP, Angonin R, et al. Sweet's syndrome associated with cutaneous T cell lymphoma. Eur J Dermatol 1998; 8:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/27\">",
"      Cho KH, Han KH, Kim SW, et al. Neutrophilic dermatoses associated with myeloid malignancy. Clin Exp Dermatol 1997; 22:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/28\">",
"      Lear JT, Byrne JP. Bullous pyoderma gangrenosum, Sweet's syndrome and malignancy. Br J Dermatol 1997; 136:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/29\">",
"      Deguchi M, Tsunoda T, Yuda F, Tagami H. Sweet's syndrome in acute myelogenous leukemia showing dermal infiltration of leukemic cells. Dermatology 1997; 194:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/30\">",
"      Woodrow SL, Munn SE, Basarab T, Russel Jones R. Sweet's syndrome in association with non-Hodgkin's lymphoma. Clin Exp Dermatol 1996; 21:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/31\">",
"      Colovi�� MD, Jankovi�� GM, Novak AZ, et al. Sweet's syndrome associated with paracentric inversion of chromosome 3q in a patient with multiple myeloma. Eur J Haematol 1996; 57:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/32\">",
"      Heer-Sonderhoff AH, Arning M, Wehmeier A, et al. Neutrophilic dermal infiltrates in granulocytopenic patients with acute leukemia. Ann Hematol 1995; 71:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/33\">",
"      Shirono K, Kiyofuji C, Tsuda H. Sweet's syndrome in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid. Int J Hematol 1995; 62:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/34\">",
"      Yamamoto T, Furuse Y, Nishioka K. Sweet's syndrome with small cell carcinoma of the lung. J Dermatol 1994; 21:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/35\">",
"      van Kamp H, van den Berg E, Timens W, et al. Sweet's syndrome in myeloid malignancy: a report of two cases. Br J Haematol 1994; 86:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/36\">",
"      Inan&ccedil; SE, Altum M, Onat H, Erseven G. Sweet's syndrome and Hodgkin's disease. Acta Oncol 1994; 33:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/37\">",
"      Barnadas MA, Sitj&agrave;s D, Brunet S, et al. Acute febrile neutrophilic dermatosis (Sweet's syndrome) associated with prostate adenocarcinoma and a myelodysplastic syndrome. Int J Dermatol 1992; 31:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/38\">",
"      Kramers C, Raemaekers JM, van Baar HM, et al. Sweet's syndrome as the presenting symptom of hairy cell leukemia with concomitant infection by Mycobacterium kansasii. Ann Hematol 1992; 65:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/39\">",
"      Torralbo A, Herrero JA, del-Rio E, et al. Sweet's syndrome associated with multiple myeloma. Int J Dermatol 1992; 31:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/40\">",
"      Uchida H, Ikari Y, Hashizume S, et al. A case of Sweet's syndrome with early gastric cancer. Dermatologica 1990; 181:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/41\">",
"      Fischer G, Commens C, Bradstock K. Sweet's syndrome in hairy cell leukemia. J Am Acad Dermatol 1989; 21:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/42\">",
"      Tuncer AM. Acute lymphoblastic leukemia and Sweet's syndrome. Acta Haematol 1988; 80:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/43\">",
"      Visani G, Patrizi AL, Ricci P, et al. Sweet's syndrome: association with accelerated phase of chronic myeloid leukemia. Acta Haematol 1988; 79:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/44\">",
"      Nguyen KQ, Hurst CG, Pierson DL, Rodman OG. Sweet's syndrome and ovarian carcinoma. Cutis 1983; 32:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/45\">",
"      Cohen PR, Talpaz M, Kurzrock R. Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol 1988; 6:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/46\">",
"      Cohen PR, Holder WR, Tucker SB, et al. Sweet syndrome in patients with solid tumors. Cancer 1993; 72:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/47\">",
"      Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol 1996; 34:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/48\">",
"      Su WP, Liu HN. Diagnostic criteria for Sweet's syndrome. Cutis 1986; 37:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/49\">",
"      Magro CM, De Moraes E, Burns F. Sweet's syndrome in the setting of CD34-positive acute myelogenous leukemia treated with granulocyte colony stimulating factor: evidence for a clonal neutrophilic dermatosis. J Cutan Pathol 2001; 28:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/50\">",
"      White JM, Mufti GJ, Salisbury JR, du Vivier AW. Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol 2006; 31:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/51\">",
"      Treton X, Joly F, Alves A, et al. Azathioprine-induced Sweet's syndrome in Crohn's disease. Inflamm Bowel Dis 2008; 14:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/52\">",
"      Juanola X, Nolla JM, Servitje O, Valverde J. Hydralazine induced lupus and Sweet's syndrome. J Rheumatol 1991; 18:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/53\">",
"      Thibault MJ, Billick RC, Srolovitz H. Minocycline-induced Sweet's syndrome. J Am Acad Dermatol 1992; 27:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/54\">",
"      Mensing H, Kowalzick L. Acute febrile neutrophilic dermatosis (Sweet's syndrome) caused by minocycline. Dermatologica 1991; 182:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/55\">",
"      Park CJ, Bae YD, Choi JY, et al. Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid. Korean J Intern Med 2001; 16:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/56\">",
"      Arun B, Berberian B, Azumi N, et al. Sweet's syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia. Leuk Lymphoma 1998; 31:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/57\">",
"      Kim MJ, Choe YH. EPONYM. Sweet syndrome. Eur J Pediatr 2010; 169:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/58\">",
"      Voelter-Mahlknecht S, Bauer J, Metzler G, et al. Bullous variant of Sweet's syndrome. Int J Dermatol 2005; 44:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/59\">",
"      Escallier F, Gaudard S, Courtois JM, et al. [Sweet's syndrome and Yersinia enterocolitica infection]. Ann Dermatol Venereol 1990; 117:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/60\">",
"      O'Connor Reina C, Garcia Iriarte MT, Rodriguez Diaz A, et al. Tonsil cancer and Sweet's syndrome. Otolaryngol Head Neck Surg 1998; 119:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/61\">",
"      Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol 2004; 140:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/62\">",
"      Shinojima Y, Toma Y, Terui T. Sweet syndrome associated with intrahepatic cholangiocarcinoma producing granulocyte colony-stimulating factor. Br J Dermatol 2006; 155:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/63\">",
"      Tanaka N, Fujioka A, Tajima S, et al. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol 2000; 143:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/64\">",
"      Reuss-Borst MA, M&uuml;ller CA, Waller HD. The possible role of G-CSF in the pathogenesis of Sweet's syndrome. Leuk Lymphoma 1994; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/65\">",
"      Loraas A, Waage A, Lamvik J. Cytokine response pattern in Sweet's syndrome associated with myelodysplasia. Br J Haematol 1994; 87:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/66\">",
"      Reuss-Borst MA, Pawelec G, Saal JG, et al. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol 1993; 84:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/67\">",
"      Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 1998; 39:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/68\">",
"      Mijovic A, Novak A, Medenica L. Sweet's syndrome associated with inversion of chromosome 3q in a patient with refractory anemia. Eur J Haematol 1992; 49:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/69\">",
"      Billstr&ouml;m R, Heim S, Kristoffersson U, et al. Structural chromosomal abnormalities of 3q in myelodysplastic syndrome/acute myeloid leukaemia with Sweet's syndrome. Eur J Haematol 1990; 45:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/70\">",
"      Kemmett D, Harrison DJ, Hunter JA. Antibodies to neutrophil cytoplasmic antigens: serologic marker for Sweet's syndrome. J Am Acad Dermatol 1991; 24:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/71\">",
"      Takahama H, Kanbe T. Neutrophilic dermatosis of the dorsal hands: a case showing HLA B54, the marker of Sweet's syndrome. Int J Dermatol 2010; 49:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/72\">",
"      Mizoguchi M, Matsuki K, Mochizuki M, et al. Human leukocyte antigen in Sweet's syndrome and its relationship to Beh&ccedil;et's disease. Arch Dermatol 1988; 124:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/73\">",
"      von den Driesch P, Weber MF. Are antibodies to neutrophilic cytoplasmic antigens (ANCA) a serologic marker for Sweet's syndrome? J Am Acad Dermatol 1993; 29:666.",
"     </a>",
"    </li>",
"    <li>",
"     Moschella SL, Davis M. Neutrophilic dermatoses. In: Dermatology, Bolognia JL, Jorizzo JL, Rapini RP.  (Eds), Elsevier, 2008. Vol 1, p.379.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/75\">",
"      Guhl G, Garc&iacute;a-D&iacute;ez A. Subcutaneous sweet syndrome. Dermatol Clin 2008; 26:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/76\">",
"      Cohen PR. Subcutaneous Sweet's syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis. J Am Acad Dermatol 2005; 52:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/77\">",
"      Walling HW, Snipes CJ, Gerami P, Piette WW. The relationship between neutrophilic dermatosis of the dorsal hands and sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum. Arch Dermatol 2006; 142:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/78\">",
"      Kroshinsky D, Alloo A, Rothschild B, et al. Necrotizing Sweet syndrome: a new variant of neutrophilic dermatosis mimicking necrotizing fasciitis. J Am Acad Dermatol 2012; 67:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/79\">",
"      Surovy AM, Pelivani N, Hegyi I, et al. Giant cellulitis-like Sweet Syndrome, a new variant of neutrophilic dermatosis. JAMA Dermatol 2013; 149:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/80\">",
"      Bamelis M, Boyden B, Sente F, Madoe V. Sweet's syndrome and acute myelogenous leukemia in a patient who presented with a sudden massive swelling of the tongue. Dermatology 1995; 190:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/81\">",
"      Gottlieb CC, Mishra A, Belliveau D, et al. Ocular involvement in acute febrile neutrophilic dermatosis (Sweet syndrome): new cases and review of the literature. Surv Ophthalmol 2008; 53:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/82\">",
"      Medenblik-Frysch S, von den Driesch P, Jonas JB, Meythaler FH. Ocular complications in Sweet's syndrome. Am J Ophthalmol 1992; 114:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/83\">",
"      Vanourny J, Swick BL. Sweet syndrome with systemic inflammatory response syndrome. Arch Dermatol 2012; 148:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/84\">",
"      Sawicki J, Morton RA, Ellis AK. Sweet syndrome with associated systemic inflammatory response syndrome: an ultimately fatal case. Ann Allergy Asthma Immunol 2010; 105:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/85\">",
"      Otheo E, Ros P, V&aacute;zquez JL, et al. Systemic inflammatory response syndrome associated with Sweet's syndrome. Pediatr Crit Care Med 2002; 3:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/86\">",
"      von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 1994; 31:535.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. The vasculopathic reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/88\">",
"      Malone JC, Slone SP, Wills-Frank LA, et al. Vascular inflammation (vasculitis) in sweet syndrome: a clinicopathologic study of 28 biopsy specimens from 21 patients. Arch Dermatol 2002; 138:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/89\">",
"      Lin J, Zhang Q, Chen M. Subcutaneous histiocytoid Sweet's syndrome in a patient associated with myelodysplastic syndrome-refractory anemia. J Dermatol 2012; 39:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/90\">",
"      Kaiser R, Connolly K, Linker C, et al. Stem cell transplant for myelodysplastic syndrome-associated histiocytoid Sweet's syndrome in a patient with arthritis and myalgias. Arthritis Rheum 2008; 59:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/91\">",
"      Spencer B, Nanavati A, Greene J, Butler DF. Dapsone-responsive histiocytoid Sweet's syndrome associated with Crohn's disease. J Am Acad Dermatol 2008; 59:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/92\">",
"      Wu AJ, Rodgers T, Fullen DR. Drug-associated histiocytoid Sweet's syndrome: a true neutrophilic maturation arrest variant. J Cutan Pathol 2008; 35:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/93\">",
"      Chow S, Pasternak S, Green P, et al. Histiocytoid neutrophilic dermatoses and panniculitides: variations on a theme. Am J Dermatopathol 2007; 29:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/94\">",
"      Requena L, Kutzner H, Palmedo G, et al. Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol 2005; 141:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/95\">",
"      Wasson S, Govindarajan G, Folzenlogen D. Concurrent occurrence of Sweet's syndrome and erythema nodosum: an overlap in the spectrum of reactive dermatoses. Clin Rheumatol 2006; 25:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/96\">",
"      Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40905/abstract/97\">",
"      Gainon J, Bart PA, Waeber G. [Can we predict the risk of malignancy associated with dermatomyositis?]. Praxis (Bern 1994) 2003; 92:1734.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13784 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40905=[""].join("\n");
var outline_f39_60_40905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3380028\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30497559\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1950250\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1950288\">",
"      Classical Sweet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1950295\">",
"      Malignancy-associated Sweet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1950361\">",
"      Drug-induced Sweet syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30497566\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30497573\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30497594\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1955675\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H704799\">",
"      Oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H704827\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30497601\">",
"      Extracutaneous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H691464001\">",
"      Associated laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1955716\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H705447\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H705454\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12627044\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2457524\">",
"      - Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12627162\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2457599\">",
"      Pathology findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H705462\">",
"      - Serologic and other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H565690\">",
"      Evaluation for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H705609\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3380028\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13784\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13784|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/12/25794\" title=\"picture 1A\">",
"      Sweet syndrome plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/61/40916\" title=\"picture 1B\">",
"      Sweet syndrome plaques on forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/46/44769\" title=\"picture 1C\">",
"      Sweet syndrome plaques on arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/36/29252\" title=\"picture 1D\">",
"      Sweet syndrome plaques on legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/11/1204\" title=\"picture 1E\">",
"      Sweet syndrome facial lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/29/41426\" title=\"picture 1F\">",
"      Sweet syndrome in childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/42/33443\" title=\"picture 2A\">",
"      Sweet syndrome bulla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/13/43221\" title=\"picture 2B\">",
"      Sweet syndrome vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/52/41806\" title=\"picture 3\">",
"      Sweet syndrome II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/26/13730\" title=\"picture 4\">",
"      Neutrophilic dermatosis hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/51/34613\" title=\"picture 5\">",
"      Sweet syndrome - histopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13784|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/37/14940\" title=\"table 1\">",
"      Diagnostic criteria for Sweet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/58/23469\" title=\"table 2\">",
"      Medications associated with drug-induced Sweet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/40/3726\" title=\"table 3\">",
"      Clinical features of Sweet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/19/31036\" title=\"table 4\">",
"      Histologic differential diagnosis of Sweet syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=related_link\">",
"      Panniculitis: Recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/10/21671?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_60_40906="Secondary prevention of cardiovascular disease";
var content_f39_60_40906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary prevention of cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/60/40906/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40906/contributors\">",
"     Charles H Hennekens, MD, DrPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40906/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/60/40906/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40906/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/60/40906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/60/40906/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/60/40906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with established coronary heart disease (CHD) have a high risk of subsequent cardiovascular events, including myocardial infarction (MI), stroke, and death from cardiovascular disease (CVD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/1\">",
"     1",
"    </a>",
"    ]. Therapeutic lifestyle changes which include identification and treatment of established risk factors, especially hypertension, dyslipidemia, smoking,",
"    <span class=\"nowrap\">",
"     obesity/poor",
"    </span>",
"    diet, physical inactivity and diabetes, are primary and major strategies to diminish premature morbidity and mortality from CVD and are recommended in many societal guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Established risk factors for atherosclerotic CVD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link&amp;anchor=H3#H3\">",
"     \"Screening for diabetes mellitus\", section on 'Type 2 diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic lifestyle changes in the form of increased physical activity, dietary",
"    <span class=\"nowrap\">",
"     modification/weight",
"    </span>",
"    loss, and smoking cessation are of proven benefit and may improve outcomes in as quickly as six months. The adjunctive drug therapies of proven benefit include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , statins, and, in patients with MI or heart failure, beta blockers and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Therapeutic lifestyle changes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The efficacy of risk factor reduction and other adjunctive therapies for the secondary prevention of CVD will be reviewed here. The efficacy of cardiac rehabilitation programs in improving outcomes in patients with coronary artery disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=see_link\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"    </a>",
"    .) The secondary prevention of ischemic stroke is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Patients with coronary heart disease risk equivalents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients without known CHD have a risk of subsequent cardiovascular events that is equivalent to that of patients with established coronary disease. All patients with a CHD risk equivalent should be managed as aggressively as those with prior CHD.",
"   </p>",
"   <p>",
"    The Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) published in 2002 classified high-risk patients with a prior CVD event or a CHD risk equivalent into three groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14525374\">",
"    <span class=\"h3\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CHD have increased risks of MI as well as noncoronary atherosclerotic vascular disease, such as stroke. The magnitude of these increased risks was quantified in a community-based study of 2160 patients with an acute MI who were followed for a median of 5.6 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In the first 30 days, the rate of first stroke was increased 44-fold compared to the general population (2.3 per 100 person-months). After this early post-MI period, the stroke risk fell by more than 90 percent but remained two to three times higher than expected for the first three years. The occurrence of a stroke after MI was associated with an almost threefold increase in mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Noncoronary atherosclerotic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As defined by ATP III, noncoronary atherosclerotic arterial disease includes patients with carotid artery disease, peripheral artery disease, or abdominal aortic aneurysm, all of whom have a 10-year risk of CHD &gt;20 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Multiple risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without prior CHD but with multiple risk factors that confer a 10-year risk of CHD &gt;20 percent are considered to have a CHD risk equivalent. The 10-year risk of CHD is assessed using the ATP III modification of the Framingham risk score (",
"    <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"mobipreview.htm?30/1/30751\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients include those with the metabolic syndrome. In a random sample of the United States population, using the ATP III definition, 40 percent of patients age 40 and over have metabolic syndrome and their average risk of a first CHD event over 10 years is 16 to 18 percent. Thus, many patients with metabolic syndrome need to be managed as aggressively as patients with prior CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link&amp;anchor=H7#H7\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\", section on 'Prevalence and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early evidence supporting diabetes as a CHD equivalent derived from a large prospective cohort study in which patients with type 2 diabetes without a prior MI were at the same risk for CHD events as nondiabetic patients who had had a prior MI (mean age 56 to 58 years in both groups) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/9\">",
"     9",
"    </a>",
"    ]. At seven years, the incidence of fatal or nonfatal MI was 20 and 19 percent for these two groups, respectively (",
"    <a class=\"graphic graphic_figure graphicRef80251 \" href=\"mobipreview.htm?34/1/34845\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Diabetes as a CHD equivalent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other observational study data, however, have found that patients with diabetes, but without CHD, have a lower rate of CHD events than those without diabetes but with prior CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/10\">",
"     10",
"    </a>",
"    ]. These discrepancies may, however, be more apparent than real and may be confounded by age and duration of diabetes, both independent risk factors for CHD.",
"   </p>",
"   <p>",
"    Subgroup analyses of diabetics randomized in the Heart Protection Study contributed to the formulation of the hypothesis of lipid lowering with 40 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    in diabetic patients without prior CHD to reduce risks of subsequent CVD events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized evidence from the CARDS trial supports the recommendation to treat patients with diabetes with a statin. CARDS was a randomized, double blind, placebo-controlled primary prevention trial among diabetics testing 10 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    . After three years of a planned five-year duration, the Steering Committee accepted the unanimous recommendation of the Data and Safety Monitoring Board to terminate the trial early due to the emergence of a statistically extreme 37 percent reduction in the primary endpoint.",
"   </p>",
"   <p>",
"    In addition to these groups of high-risk patients there are other categories considered by other agencies in their guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Kidney Foundation (NKF) and the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on ST elevation myocardial infarction recommended that chronic kidney disease be considered a CHD risk equivalent, based upon evidence that renal dysfunction (even of mild degree) is associated with an increase in CHD risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. While these guidelines did not give a precise definition of significant renal dysfunction, it may be defined by a serum creatinine concentration that exceeds 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     &micro;mol/L]",
"    </span>",
"    or an estimated glomerular filtration rate that is less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is not a major independent risk factor in the development of CHD, but occurs frequently in patients with established CVD and is associated with increased morbidity and mortality. The 2008 American Heart Association (AHA) scientific advisory on Depression and Coronary Heart Disease recommends screening for depressive symptoms in such patients and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Screening for depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=see_link&amp;anchor=H16#H16\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\", section on 'Depression and psychosocial stress post MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The AHA advisory recommends the Patients Health Questionnaire (PHQ-2) for screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/18\">",
"     18",
"    </a>",
"    ]. Using this tool, the provider asks the patient the following two part question:",
"   </p>",
"   <p>",
"    Over the past two weeks, how often have you been bothered by any of the following problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Little interest or pleasure in doing things.",
"     </li>",
"     <li>",
"      Feeling down, depressed, or hopeless.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A \"yes\" answer to either part should prompt the practitioner to arrange for a more comprehensive evaluation by a qualified professional.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk reduction therapy is recommended for all patients with atherosclerotic cardiovascular disease in the 2011 American Heart Association",
"    <span class=\"nowrap\">",
"     (AHA)/American",
"    </span>",
"    College of Cardiology Foundation (ACCF) guideline on secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ]. In patients with CHD, these measures are referred to as \"secondary prevention,\" or prevention of complications due to established disease. In addition, however, equally intensive risk factor modification is recommended in patients with CHD risk equivalent.",
"   </p>",
"   <p>",
"    Based upon numerous randomized trials of statins published after ATP III, including those with active statin comparators, the Coordinating Committee of the National Cholesterol Education Program (NCEP) of the National Heart, Lung and Blood Institute proposed modifications to the ATP III guidelines in July 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/6\">",
"     6",
"    </a>",
"    ], which were endorsed by the ACC and AHA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/14\">",
"     14",
"    </a>",
"    ]. They defined a group of \"very high risk\" patients (",
"    <a class=\"graphic graphic_table graphicRef54585 \" href=\"mobipreview.htm?10/56/11147\">",
"     table 2",
"    </a>",
"    ) and recommended more aggressive risk-factor modification for such patients, specifically with respect to lipid modification.",
"   </p>",
"   <p>",
"    Risk-factor modification for secondary prevention will be reviewed here, with the evidence supporting each of the recommended modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/6\">",
"     6",
"    </a>",
"    ]. More detailed discussions of each risk factor are presented elsewhere on the appropriate topic reviews as is the efficacy of primary prevention of CVD and stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282986510\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education regarding",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    risk factors and their management is central to secondary prevention. We agree with the following points made in 2012",
"    <span class=\"nowrap\">",
"     ACCF/AHA/ACP/AATS/PCNA/SCAI/STS",
"    </span>",
"    guideline for the diagnosis and management of patients with stable ischemic heart disease (SIHD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with SIHD should have an individualized education plan to optimized care and promote wellness that includes education on medication adherence, an explanation of medication management and cardiovascular risk reduction strategies in a manner that respects the patient&rsquo;s level of understanding, a comprehensive review of all therapeutic options, a description of appropriate levels of exercise, introduction to self-monitoring skills, and information on how to recognize worsening cardiovascular symptoms and take appropriate action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LIPID MODIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective observational cohort studies have shown a curvilinear relationship between the serum cholesterol concentration and subsequent risk of CHD. More recently, randomized trials and their meta-analyses show similar findings.",
"   </p>",
"   <p>",
"    Secondary prevention patients with established CHD have far higher absolute risks of recurrent events than the majority of primary prevention subjects (",
"    <a class=\"graphic graphic_figure graphicRef60146 graphicRef50334 \" href=\"mobipreview.htm?26/27/27070\">",
"     figure 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the past two decades, many large randomized trials of secondary prevention in patients with prior CVD events, have demonstrated the benefit of lipid lowering, with statin therapy on subsequent risks of MI, stroke, and CVD events. Statin therapy lowers the risk of death by 15 to 20 percent and lowers the risk of non-fatal cardiovascular events by an even greater degree. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Effects of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In subgroup analyses, the data from these trials have led to the formulation of the hypothesis that, as regards statin therapy, lower is better with regard to serum cholesterol, particularly low density lipoprotein cholesterol (LDL-cholesterol). This hypothesis was tested in a number of active comparator trials which did not compare a higher LDL-cholesterol target to a lower one, but rather one dose of a statin to either another dose of the same statin (or another statin). Thus, the benefit seen in these trials could be due to a greater degree of LDL-cholesterol lowering or to pleiotropic effects of a higher statin dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The secondary prevention trials of lipid modification with statins also demonstrated statistically significant and clinically important reductions in stroke. Meta-analyses contributed to the formulation of the hypothesis that statin therapy compared to placebo results in a significant 30 percent reduction in stroke over a wide range of lipid values. The individual randomized trials indicated similar benefits of statins primarily due to significant reductions in ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184471343\">",
"    <span class=\"h2\">",
"     Residual risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite important improvement in outcomes with statin therapy, many optimally treated patients experience one or more adverse outcomes. In a meta-analysis of nearly 29,000 patients with CVD in 14 randomized trials comparing statin to no statin, 21.2 percent of treated patients experienced a major cardiovascular event during five years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The determinants of the residual risk of an event were evaluated in a study of 9251 CHD patients with LDL-C &lt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    in the TNT study. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'TNT trial'",
"    </a>",
"    .) Multivariable determinants identified were older age, increased body-mass index, male gender, hypertension, diabetes, baseline apolipoprotein B, and blood urea nitrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/27\">",
"     27",
"    </a>",
"    ]. These findings highlight the importance of aggressively treating all modifiable risk factors in patients with established cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that all patients with atherosclerotic CVD be treated with at least a moderate dose of a statin, irrespective of the baseline LDL-cholesterol, including those whose baseline LDL-cholesterol is below the goals set below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H13#H13\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ATP III guidelines published in 2001 recommended that the goal LDL-cholesterol should be less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in all high-risk patients including secondary prevention and in those with a coronary equivalent including diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/1\">",
"     1",
"    </a>",
"    ]. This goal for high-risk patients was also recommended by the 2011",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    guideline for secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ]. This guideline also recommended a LDL-cholesterol goal of less than 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for patients a very high risk, such as those with established CVD plus multiple major risk factors, severe and poorly controlled risk factors, multiple risk factors of the metabolic syndrome, and patients with acute coronary syndromes.",
"   </p>",
"   <p>",
"    Diabetes has been considered a coronary risk equivalent, but the patient specific risk should be calculated, prior to recommending statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H1033672373#H1033672373\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Diabetes mellitus as a CHD equivalent'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the totality of evidence to date, especially the statistically significant and clinically important overall results of PROVE-IT-TIMI 22 and TNT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/23,28\">",
"     23,28",
"    </a>",
"    ], we suggest a target LDL-C concentration &le;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in patients with established CHD; with CHD equivalents such as noncoronary atherosclerotic vascular disease, or chronic kidney disease; and in patients with multiple risk factors that confer a 10-year risk of CHD &gt;20 percent. This recommendation is supported by results of individual trials as well as a comprehensive world-wide patient level meta-analysis of all active comparator trials of statins designed a priori to test the hypothesis.",
"   </p>",
"   <p>",
"    Some have recommended a less aggressive approach based upon their interpretation of small increases in side effects at higher dose statin therapy, cost of the these medications, and the absence of a benefit on total mortality in many trials, despite the fact that none was designed a priori to test this hypothesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H13#H13\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both therapeutic lifestyle changes, including dietary modification and increased levels of physical activity as well as adjunctive drug therapy with statins should be used to achieve the goals (",
"    <a class=\"graphic graphic_table graphicRef78862 \" href=\"mobipreview.htm?40/16/41227\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef82504 \" href=\"mobipreview.htm?11/4/11340\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Statins are first-line drugs for virtually all patients who present with dyslipidemia, since they have proven benefits on MI, stroke and CVD death and produce marked decreases in LDL-cholesterol and triglycerides, and modest increases in HDL-cholesterol. In addition, the totality of evidence from randomized trials, including morbidity and mortality benefits, is far larger and far more persuasive for statins than any other modalities. Finally, statins, especially those of higher potency, appear to have pleiotropic effects beyond LDL-cholesterol lowering, which produce clinical benefits within weeks to months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with a serum triglyceride concentration &ge;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.26",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    ATP III defined the appropriate target of therapy to be non-HDL-cholesterol rather than LDL-cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/1\">",
"     1",
"    </a>",
"    ]. Non-HDL-cholesterol is defined as the difference between the total cholesterol and HDL-cholesterol. The goal for non-HDL-cholesterol in this setting is a concentration that is 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.78",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    higher than that for LDL cholesterol (",
"    <a class=\"graphic graphic_table graphicRef53318 \" href=\"mobipreview.htm?2/46/2795\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link&amp;anchor=H14#H14\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\", section on 'Non-HDL-cholesterol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with an acute MI or unstable angina who are not already being treated, statin therapy should be initiated prior to discharge. This recommendation is based, in part, upon the data from PROVE IT-TIMI 22 that revealed a significant benefit that was apparent within one month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/28\">",
"     28",
"    </a>",
"    ]. Based upon the results of PROVE IT-TIMI 22, we recommend therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in all patients with an ACS. Initial intensive therapy, rather than gradual dose titration upward, is recommended, in part, because most patients remain at their initial dose and also because of the suggestion in PROVE IT-TIMI 22 of benefit within 30 days, an interval before the first serum cholesterol measurement on therapy would usually be obtained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of the response of lipids to statin therapy after an acute coronary syndrome should be deferred for two months, since acute phase responses and perhaps other factors can transiently lower LDL-cholesterol by 40 to 50 percent and thus, in some patients, cause spuriously normal-appearing levels following an acute coronary syndrome (",
"    <a class=\"graphic graphic_figure graphicRef67633 \" href=\"mobipreview.htm?7/47/7933\">",
"     figure 3",
"    </a>",
"    ). The magnitude of this effect, at least soon after hospitalization, appears to be less with current therapies that limit the degree of myocardial injury, such as percutaneous coronary intervention or fibrinolytic therapy. These issues are discussed elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31222?source=see_link\">",
"     \"Measurement of serum lipids and lipoproteins\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The long-term goal for serum LDL-cholesterol is less than 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Recurrent events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit that intensive statin therapy reduces not only a first CV event, but also recurrent events as compared with standard statin therapy has been documented in three trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possible options include the addition of other agents such as fibrates, niacin, fish oil, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    , although the totality of evidence is far smaller and less persuasive. In addition, although direct randomized evidence is accumulating at present, none of these agents has been shown to improve clinical cardiovascular disease outcomes beyond that achieved with statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Possible role of CRP",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested evaluating the C-reactive protein (CRP) response after optimal statin therapy and implementing further treatment to reduce elevated serum CRP. This approach is in part based upon subgroup analyses from PROVE IT-TIMI 22 that patients with serum CRP values &ge;2",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    had higher risks of cardiovascular events than those with lower levels (3.9 versus 2.8 per 100 patient-years), even in patients with posttreatment serum LDL-cholesterol values below 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L;",
"    </span>",
"    3.1 versus 2.4 per 100 patient-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/32\">",
"     32",
"    </a>",
"    ]. These findings indicate no effect modification by LDL-cholesterol in the ability of CRP to predict cardiovascular events, but do not necessarily imply that the CRP benefit is independent of LDL-cholesterol. In fact, in a meta-analysis of observational epidemiological studies, LDL was a far more important predictor of subsequent CVD events than CRP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in phase Z of the A-to-Z trial in which achieved levels of serum CRP at 30 days and four months after ACS were associated with long-term survival irrespective of treatment assignment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/34\">",
"     34",
"    </a>",
"    ]. Lower CRP levels were more likely to be attained in patients treated with higher doses of a statin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link&amp;anchor=H23#H23\">",
"     \"C-reactive protein in cardiovascular disease\", section on 'Reduction in coronary risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, there is no consensus on a threshold level to define \"elevated\" serum CRP, although a statement from the Centers for Disease Control and Prevention and the American Heart Association published in 2003 proposed definitions of low-, intermediate-, and high-risk levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies have questioned the additional contribution of measuring CRP in the clinical setting. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Heart Protection Study'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since there is no evidence from randomized trials about the efficacy of further drug therapy targeted to CRP goals, most experts would not modify management further if serum CRP remains elevated after these steps. A clinical decision to implement additional drug treatment, which could include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients not already receiving maximal statin therapy (eg, 80 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      or 40 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      ), an increase in statin dose or a change to a more potent statin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link\">",
"       \"Statins: Actions, side effects, and administration\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The addition of other classes of lipid lowering drugs including fibrates, niacin, fish oil or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      . However, as mentioned above, none of these drugs has been shown to improve clinical outcomes beyond that achieved with statin therapy. In addition, a meta-analysis of the over 90,000 patients randomized in statin trials shows statistically significant and clinically important benefits on subsequent MI, stroke, cardiovascular death, and total mortality. Interestingly, in five years of treatment and follow-up, there were 15 incident cases of rhabdomyolysis, nine in the statin group and six in the control group. This totality of randomized evidence is more than tenfold greater than for any other adjunctive therapy. Further, the benefits of niacin and fish oil were achieved in the absence of statins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link\">",
"       \"Lipid lowering with fibric acid derivatives\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=see_link\">",
"       \"Lipid lowering with drugs other than statins and fibrates\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     HDL-cholesterol and triglycerides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion has emphasized the importance of control of serum LDL-cholesterol as well as possible benefits of statin therapy that are unrelated to lipid lowering. In addition, low HDL-cholesterol and high triglycerides each appear to contribute independently to cardiovascular risk and the combination is associated with a greater likelihood of other features of the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of raising serum low HDL-cholesterol or lowering triglycerides in patients with CHD was demonstrated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    in the VA-HIT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/38\">",
"     38",
"    </a>",
"    ] and with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    and niacin in a smaller trial of similar patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the VA-HIT trial, 2531 patients with CHD with a low HDL-cholesterol (&le;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.0",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    a low LDL-cholesterol (&le;140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 3.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and triglyceride levels &le;300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/38\">",
"     38",
"    </a>",
"    ]. At five years, the combined primary endpoint of cardiac death and nonfatal MI occurred significantly less often in the gemfibrozil group (17.3 versus 21.7 percent for placebo). The beneficial effect did not become apparent until two years after randomization. Patients taking gemfibrozil also had a lower rate of stroke (4.6 versus 6 percent for placebo), transient ischemic attacks (1.7 versus 4.2 percent), and carotid endarterectomy (1.3 versus 3.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/40\">",
"     40",
"    </a>",
"    ]. The reduction in stroke risk was evident after 6 to 12 months of therapy.",
"   </p>",
"   <p>",
"    However, 38 percent of the cases of rhabdomyolysis in the United States Food and Drug Administration data base are attributable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    either alone or in combination with statins.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    has less potential for such toxicity and is the preferred fibrate in patients treated with a statin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link&amp;anchor=H301173455#H301173455\">",
"     \"Statin myopathy\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is recommended that, for secondary prevention, patients who have a persistently low HDL-cholesterol concentration (&lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.03",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    after the goal LDL-cholesterol concentration has been achieved with a statin should be started on nonpharmacologic therapy (eg, exercise, smoking cessation, weight loss in obese subjects); nicotinic acid or a fibrate can be added if this is ineffective. Large trial results with the use of niacin, however, have been disappointing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H708622578#H708622578\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'AIM-HIGH trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with low HDL-cholesterol concentrations also have elevated triglycerides. The goal for triglycerides is less than 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    which may be achieved with statins alone or the addition of adjunctive therapies, such as fish oil or fibrates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Stroke Council of the American Heart Association and the American Stroke Association recommended in 2004 that statins should be started during hospitalization for all patients with transient ischemic attack or first stroke of atherosclerotic origin who are not already being treated, regardless of serum total cholesterol or LDL-cholesterol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H10#H10\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Dyslipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CONTROL OF HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The seventh Joint National Committee (JNC 7) report proposed the following definitions based upon the average of two or more properly measured readings at each of two or more visits after an initial screen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal blood pressure &mdash; systolic &lt;120 mmHg and diastolic &lt;80 mmHg",
"     </li>",
"     <li>",
"      Prehypertension &mdash; systolic 120-139 mmHg or diastolic 80-89 mmHg",
"     </li>",
"     <li>",
"      Hypertension &mdash; systolic &ge;140 mmHg or diastolic &ge;90 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with prehypertension have higher rates of progression to overt hypertension as well as increases in cardiovascular mortality (",
"    <a class=\"graphic graphic_figure graphicRef75106 graphicRef66793 \" href=\"mobipreview.htm?33/12/33986\">",
"     figure 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef82189 \" href=\"mobipreview.htm?42/40/43662\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44677?source=see_link\">",
"     \"Prehypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most reliable evidence that pharmacologic treatment of mild to moderate hypertension decreases risks of cardiovascular complications comes from large-scale randomized trials designed a priori to test the hypothesis and their meta-analyses. In a comprehensive patient level meta-analysis of trials of patients with mild to moderate hypertension, lowering the blood pressure with antihypertensive therapy by 4-5 mmHg reduces the rate of stroke by about 40 percent and CHD by about 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/46\">",
"     46",
"    </a>",
"    ]. Not surprisingly, the presence of other risk factors influences treatment decisions (",
"    <a class=\"graphic graphic_table graphicRef72683 \" href=\"mobipreview.htm?34/41/35484\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Therapeutic lifestyle changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major societal guidelines recommend therapeutic lifestyle changes (TLC)s for all apparently healthy individuals with a blood pressure of",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/14,42,47\">",
"     14,42,47",
"    </a>",
"    ]. Appropriate measures include moderate dietary sodium restriction, weight reduction in the obese, avoidance of excess alcohol intake, and regular physical activity (",
"    <a class=\"graphic graphic_table graphicRef62129 \" href=\"mobipreview.htm?42/24/43403\">",
"     table 7",
"    </a>",
"    ). Institution of these TLCs involves little or no risk and all are likely to be beneficial, even in apparently healthy normotensive subjects. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Weight reduction'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link\">",
"     \"Diet in the treatment and prevention of hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=see_link\">",
"     \"Obesity and weight reduction in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal blood pressure in patients with established CVD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Choice of antihypertensive drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;General issues related to the choice of antihypertensive drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, certain underlying diseases warrant the use of specific antihypertensive drugs, independent of their effect on blood pressure (",
"    <a class=\"graphic graphic_table graphicRef63628 \" href=\"mobipreview.htm?10/53/11101\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among patients with CVD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients who have had a MI, especially those with diabetes or metabolic syndrome, should be treated with an ACE inhibitor or angiotensin II receptor blocker (ARB), as well as beta blocker, independent of BP control. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"       \"Beta blockers in the management of acute coronary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=see_link\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with stable angina may require therapy may require therapy with a beta blocker or calcium channel blocker for symptom control. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link\">",
"       \"Overview of the care of patients with stable ischemic heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     THERAPEUTIC LIFESTYLE CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic lifestyle changes have statistically significant and clinically important beneficial effects on cardiovascular morbidity and mortality and should be an integral component of any secondary prevention program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cardiac rehabilitation programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits from modification of multiple risk factors are additive, at the very least. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=see_link&amp;anchor=H8#H8\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\", section on 'Comprehensive risk factor intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2011",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    guideline on secondary prevention which recommends referral to a comprehensive outpatient cardiovascular rehabilitation program for all eligible patients with a recent acute coronary syndrome or revascularization procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ]. Other patients, such as those with these diagnoses in the past year, those with chronic angina, or those with peripheral artery disease, may be candidates for referral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation produces benefits on CVD beginning within a matter of months and reaching the nonsmoker in three to five years. These benefits have been shown in secondary and primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of 12,603 smokers who had prior MI, CABG, angioplasty, or known CHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/49\">",
"       49",
"      </a>",
"      ], the relative risk of mortality for quitters compared with those who continued to smoke was 0.64 (95% CI 0.58-0.71).",
"     </li>",
"     <li>",
"      In a cohort study of 2619 patients who survived to hospital discharge after a first MI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/50\">",
"       50",
"      </a>",
"      ], among those who quit smoking (patients who quit and restarted were considered active smokers), the risk ratio for recurrent events progressively and significantly decreased with longer duration of cessation (RR 1.62 at 0 to &lt;6 months, 1.60 from 6 to &lt;18 months, 1.48 for 18 to &lt;36 months, and 1.02 for &ge;36 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The various major effective modalities to attain and sustain smoking cessation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2011",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    guideline on secondary prevention, which recommends complete smoking cessation as well as avoidance of environmental tobacco smoke in all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Weight reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity, particularly central or abdominal obesity, is associated with increased risks for CVD. While obesity contributes to hypertension, dyslipidemia, and insulin resistance leading to diabetes among those with metabolic syndrome, the increased risks of CVD are also present for obese patients without metabolic syndrome. These issues are discussed in detail elsewhere, but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obesity is a risk factor for CHD in both men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The increase in risk is seen with increasing weight within the \"normal\" range, but is most pronounced with obesity. Using a body mass index (BMI) less than 21",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    as a reference in the Nurses' Health Study, the adjusted relative risk for CHD was 1.19 at a BMI of 21 to 22.9",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    1.46 at 23 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    2.06 at 25 to 28.9",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    (considered overweight but not obese), and 3.56 at a BMI &ge;29",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/52\">",
"     52",
"    </a>",
"    ]. The relative risk of dying from CVD at 16 years was 4.1 in women with a BMI &ge;32 compared with &lt;19",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/53\">",
"     53",
"    </a>",
"    ]. Obesity is also a risk factor for the development of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3641?source=see_link\">",
"     \"Obesity, weight reduction, and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension &mdash; It has been suggested that control of obesity would eliminate 48 percent of hypertension in whites and 28 percent in blacks. On average, the blood pressure falls 0.5 to 2.0 mmHg for every 1.0 kg of weight that is lost (",
"      <a class=\"graphic graphic_figure graphicRef60178 \" href=\"mobipreview.htm?24/34/25133\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/42,55\">",
"       42,55",
"      </a>",
"      ]. Furthermore, a sustained 4 to 5 mmHg decrease in blood pressure among those with systolic &gt;140 or diastolic &gt;90 leads to statistically significant and clinically important reductions in stroke of 42 percent and MI of 14 percent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=see_link\">",
"       \"Obesity and weight reduction in hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type 2 diabetes &mdash; Obesity is a major risk factor for insulin resistance and type 2 diabetes in both men and women, particularly when combined with a \"western\" diet (characterized by high consumption of red meat, processed meat, high-fat dairy products, sweets, and desserts) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. The risk is markedly reduced by weight loss. In the Nurses' Health study, for example, women who lost more than 5.0 kg reduced their risk for diabetes by 50 percent or more [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/57\">",
"       57",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dyslipidemia &mdash; Obesity is associated with adverse effects on several lipids including increases in total cholesterol, LDL-cholesterol, very low density lipoprotein (VLDL)-cholesterol, and triglycerides, and a reduction in HDL-cholesterol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with CVD should have measurement of waist circumference and calculation of body mass index. The 2011",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    guideline on secondary prevention recommended a target BMI of 18.5 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and a waist circumference of &lt;35 inches in women (&lt;89 cm) and &lt;40 inches in men (&lt;102 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients who exceed these parameters should undergo evaluation for the metabolic syndrome and implementation of weight reduction strategies as an integral component of their multifactorial risk factor reduction. Weight reduction is optimally achieved with a multiple strategies including diet, increased physical activity, and possible pharmacologic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    recommended a 5 to 10 percent reduction in body weight as an initial goal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular physical activity has numerous cardiovascular benefits including weight loss, improvements in lipid profile, reductions in blood pressure, as well as prevention and treatment of type 2 diabetes. These issues are discussed in detail separately but the magnitude of the effect can be illustrated by the following observations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=see_link\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2005 meta-analysis included 11 randomized trials of 2285 patients with coronary disease (most but not all post-MI) who were assigned to exercise rehabilitation or usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/58\">",
"     58",
"    </a>",
"    ]. Exercise was associated with a significant 28 percent reduction in all-cause mortality (6.2 versus 9.0 percent, summary risk ratio 0.72, 95% CI 0.54-0.95). There was also a possible, but nonsignificant, 24 percent reduction in recurrent MI in the exercise rehabilitation group (summary risk ratio 0.76, 95% CI 0.57-1.01).",
"   </p>",
"   <p>",
"    The meta-analysis also included 15 trials of 4655 patients who were randomly assigned to a combined exercise and risk factor education program or to usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/58\">",
"     58",
"    </a>",
"    ]. Rehabilitation was associated with a possible but nonsignificant 12 percent reduction in all-cause mortality (9.3 versus 10.8 percent, summary risk ratio 0.88, 95% CI 0.74-1.04) and a significant 38 percent reduction in recurrent MI (summary risk ratio 0.62, 95% CI 0.44-0.87).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2011",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    guideline on secondary prevention which recommended that, prior to starting an exercise program, all patients should undergo risk assessment with a physical activity history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an exercise test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2007 European Society of Cardiology (ESC) guidelines on CVD prevention in clinical practice, gave specific recommendations for the components of an appropriate exercise program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/2,59\">",
"     2,59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise should be performed for a minimum of 30 minutes per day, preferably daily but at least five days per week.",
"     </li>",
"     <li>",
"      Exercise should involve moderately intensive aerobic activity such as brisk walking. The ESC guidelines suggest a target heart rate of 60 to 75 percent of the average maximum heart rate or the perception of moderate exercise (12 to 14 on the Borg scale) (",
"      <a class=\"graphic graphic_table graphicRef70470 \" href=\"mobipreview.htm?20/13/20699\">",
"       table 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31417?source=see_link&amp;anchor=H10#H10\">",
"       \"Components of cardiac rehabilitation and exercise prescription\", section on 'Rating of perceived exertion (Borg scale)'",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      Exercise should be supplemented by an increase in daily lifestyle activities (eg, walking breaks at work, gardening, and household work).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Alcohol drinking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy drinkers of alcohol have by far the highest morbidity and mortality rates for CVD and death in the population. In addition, heavy alcohol consumption is a leading avoidable cause of cancer and all deaths, and is the leading cause of hospitalizations in state mental hospitals in the US. In contrast, those who consume one to two drinks daily have somewhat lower risk of CVD than nondrinkers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=see_link\">",
"     \"Overview of the risks and benefits of alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with or without underlying CVD who drink small to moderate amounts of alcohol daily have lowered risks of CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/48,60\">",
"     48,60",
"    </a>",
"    ]. In a pooled estimate from five prospective cohort studies of patients with CHD, patients who consumed small to moderate amounts of alcohol daily had a statistically significant 20 percent reduction in CVD mortality (relative risk 0.80, 95% CI 0.78-0.83) when compared with nondrinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/48\">",
"     48",
"    </a>",
"    ]. One plausible mechanism for benefit is increases in HDL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy diets are associated with lower CVD event rates in patients without established disease. Emerging evidence suggests that dietary interventions, and in particular a Mediterranean diet, improves outcomes in patients with established CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/61\">",
"     61",
"    </a>",
"    ]. Until further studies further evaluate the magnitude of benefit of a Mediterranean diet, it is reasonable to advise all such patients to adhere to its components. &nbsp;",
"   </p>",
"   <p>",
"    The 2011 American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology Foundation guidelines for secondary prevention make specific recommendations only in the context of the management of elevated blood pressure (weight control; increased consumption of fresh fruits, vegetables, and low-fat dairy products), abnormal lipids (reduce intake of saturated fats [to &lt;7 percent of total calories], trans-fatty acids [to &lt;1 percent of total calories], and cholesterol [to &lt;200 mg daily]), weight (restrict caloric intake), and diabetes mellitus (weight, blood pressure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ]. The 2012 European guidelines on CVD prevention (both primary and secondary) make a strong recommendation for a healthy diet, which is defined as having the following characteristics: saturated fatty acids &lt;10 percent of total energy intake; as little as possible of trans-unsaturated fatty acids; 30 to 45 g of fiber per day; 200 g of fruit per day; 200 g of vegetables per day; and fish at least twice a week, one of which should be oily fish [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/62\">",
"     62",
"    </a>",
"    ]. These recommendations were based primarily on observational studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\", section on 'Healthy diet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of the dietary recommendations made above are achieved with the Mediterranean diet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=see_link&amp;anchor=H20#H20\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Mediterranean diet'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=see_link&amp;anchor=H24#H24\">",
"     \"Healthy diet in adults\", section on 'Mediterranean diet'",
"    </a>",
"    .) The PREDIMED primary prevention trial randomly assigned 7447 individuals at high risk for CVD to a Mediterranean diet supplemented with olive oil, a Mediterranean diet supplemented with mixed nuts, or a diet aimed at reducing the intake of fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/63\">",
"     63",
"    </a>",
"    ]. The trial was stopped early after a median follow-up of 4.8 years. The combined primary end point (myocardial infarction, stroke, or cardiovascular death) occurred significantly less often in the two intervention groups (any of the two types of Mediterranean diet) (8.1, 8.0, and 11.2 events per 1000 person-years, respectively; adjusted hazard ratios 0.70, 95% CI 0.54-0.92 and 0.72, 95 % CI 0.54-0.96, comparing intervention to control). This trial suggests a substantial cardiovascular benefit from a Mediterranean diet. However, the surprisingly large reduction in events in a trial with a low total number of events (288) that was stopped early for benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/64-66\">",
"     64-66",
"    </a>",
"    ] raises concerns that the apparent benefits of a Mediterranean diet could have been overestimated. We believe that the conclusions of this primary intervention trial can be extended to individuals with established atherosclerotic CVD.",
"   </p>",
"   <p>",
"    Further evidence supporting the concept that a healthy diet improves outcomes in patients with established CVD comes from a prospective cohort study of 31,546 individuals &ge;55 years of age with CVD or diabetes mellitus with end-organ damage receiving medications known to improve outcomes (eg statins, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/67\">",
"     67",
"    </a>",
"    ]. The quality of the diet was assessed with two dietary indices and patients were placed into quintiles. Components of a healthy diet included a high intake of fruits, vegetables, whole grains, and nuts and a higher intake of fish relative to meat, poultry, and eggs. During a follow-up of 56 months, there were 5690 events. The primary composite end point of cardiovascular death, myocardial infarction, stroke, or heart failure occurred less often in the top (best diet) compared to the lowest quintile (adjusted hazard ratio, 0.78, 95% CI 0.71-0.87). The benefit from a healthy diet was present regardless of whether patients were taking medications of proven benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81267106\">",
"    <span class=\"h2\">",
"     Yoga",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of yoga for secondary prevention of cardiovascular disease has not been evaluated in randomized trials. A 2012 systematic review found no eligible randomized trials of yoga for secondary prevention that met their inclusion criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     After acute coronary syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of adherence to behavioral recommendations on the risk for adverse short-term cardiovascular outcomes after an acute coronary syndrome (ACS) were demonstrated in observational data from the OASIS-5 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link&amp;anchor=H39#H39\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Fondaparinux'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this study of over 18,000 patients with non-ST elevation ACS, adherence to behavioral recommendations on diet, physical activity, and smoking cessation recommendations was collected at baseline and 30 days after the event. With respect to cardiovascular events (MI, stroke, or cardiovascular death) or all-cause mortality, at six months, after adjustment for all available risk factors and medical therapies, the following significant findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smoking cessation was associated with a 43 percent decreased risk of MI compared to persistent smoking (odds ratio 0.57, 95% CI 0.36-0.89).",
"     </li>",
"     <li>",
"      Diet and exercise adherence was associated with a 48 percent decreased risk of MI compared with nonadherence (odds ratio 0.52, 95% CI 0.4-0.69).",
"     </li>",
"     <li>",
"      Patients with persistent smoking who did not adhere to diet and exercise had a 3.8 fold (95% CI 2.5-5.9) increased risk of",
"      <span class=\"nowrap\">",
"       MI/stroke/death",
"      </span>",
"      compared with never smokers who modified their diet and exercises.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     METABOLIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the constellation of abdominal obesity, hypertension, diabetes, and dyslipidemia are considered to have the metabolic syndrome (also called the insulin resistance syndrome or syndrome X). Individuals with the metabolic syndrome have increased risks of CVD. This disorder is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     GLYCEMIC CONTROL IN DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of glycemic control on macrovascular and microvascular disease in patients with type 1 and type 2 diabetes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link&amp;anchor=H12#H12\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\", section on 'Macrovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glycemic control in-hospital and thereafter in patients who have had a MI is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=see_link\">",
"     \"Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thiazolidinediones are used in the treatment of patients with diabetes mellitus. This issue, as well as issues about the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    in patients with CHD, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    guideline did not make a strong recommendation for a specific HbA1c target, but rather emphasized the importance of lifestyle modifications and the coordinated care between the patient&rsquo;s primary care physician",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocrinologist and the",
"    <span class=\"nowrap\">",
"     cardiologist/vascular",
"    </span>",
"    specialist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Degree of glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with type 2 diabetes, with and without MI aggressive management of lipids (LDL &lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.8",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    HDL &gt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.1",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    and triglycerides &lt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.7",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    as well as blood pressure (goal systolic pressure below 130 mmHg) appear to be even more important than glycemic control. In multivariate analyses of the UKPDS trial, LDL and HDL-cholesterol were more important predictors of subsequent CVD events than blood pressure, HbA1c, and smoking, all of which were statistically significant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In secondary prevention of CVD, statistically significant and beneficial therapies include beneficial statins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, and angiotensin converting enzyme inhibitors or angiotensin receptor blockers. In some clinical settings,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    may be warranted. Finally, administration of influenza vaccine may be beneficial in patients with established coronary heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611365682\">",
"    <span class=\"h3\">",
"     Antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    reduces the risk of subsequent myocardial infarction (MI), stroke, and vascular death among patients with a wide range of manifestations of occlusive cardiovascular disease (CVD). The data supporting this conclusion and recommendations for use are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H13#H13\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monotherapy with a platelet P2Y12 receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) improves outcomes in patients with stable coronary artery disease and is particularly beneficial in the approximately 5 percent of patients who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H16#H16\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Comparison to thienopyridines'",
"    </a>",
"    .) In addition, clopidogrel monotherapy may be effective in patients with stroke and peripheral artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link&amp;anchor=H13#H13\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\", section on 'Other agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H870617049\">",
"    <span class=\"h4\">",
"     Clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothesis that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    adds to the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in long-term treatment (ie, median of 28 months) was tested in the CHARISMA trial, in which 15,603 stable patients with either clinically evident CVD (about 12,000 with coronary, cerebrovascular, or peripheral arterial) or multiple atherothrombotic risk factors (about 3000 with diabetes, which is a coronary heart disease risk equivalent, in 92 percent, hypertension in 47 percent, and primary hypercholesterolemia in 62 percent) were randomly assigned aspirin (75 to 162",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus either clopidogrel (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/72\">",
"     72",
"    </a>",
"    ]. The primary endpoint was a composite of MI, stroke, or cardiovascular death.",
"   </p>",
"   <p>",
"    The following overall findings were noted at a median of 28 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the primary endpoint (6.8 versus 7.3 percent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone, relative risk [RR] 0.93, 95% CI 0.85-1.05); there was a significant difference in the secondary endpoint of hospitalization for ischemic events (16.7 versus 17.9 percent, RR 0.92, 95% CI 0.86-0.995).",
"     </li>",
"     <li>",
"      Dual antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was associated with a significant increase in moderate bleeding (2.1 versus 1.3 percent) and a possible but nonsignificant increase in severe bleeding (1.7 versus 1.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the findings in CHARISMA, dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) improves outcomes in patients who have sustained an acute coronary syndrome or who have undergone coronary artery stent placement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H16#H16\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Clopidogrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H870616861\">",
"    <span class=\"h4\">",
"     Vorapaxar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vorapaxar is a competitive antagonist of the protease activated receptor 1 (PAR-1), the major thrombin receptor on platelets. Vorapaxar is not available for clinical use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link&amp;anchor=H6#H6\">",
"     \"Platelet biology\", section on 'PAR-1 antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The TRA 2P-TIMI 50 trial randomly assigned 26,449 patients with stable atherosclerotic cardiovascular disease (MI or ischemic stroke within the past 2 to 12 months or peripheral artery disease) and who were treated with at least one other antiplatelet drug to either vorapaxar or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/73\">",
"     73",
"    </a>",
"    ]. At three years, the primary composite end point of cardiovascular death, MI, or stroke occurred less often with vorapaxar (9.3 versus 10.5 percent; hazard ratio [HR] 0.87, 95% CI 0.80-0.94). Moderate or severe bleeding occurred significantly more often with vorapaxar (4.2 versus 2.5 percent) and the rate of intracranial hemorrhage was significantly higher with vorapaxar, particularly in those with prior stroke.",
"   </p>",
"   <p>",
"    In a prespecified subgroup analysis of 17,779 patients with prior MI, those assigned vorapaxar had a lower risk of developing the primary endpoint (8.1 versus 9.7 percent; HR 0.80, 95% CI 0.72-0.89) at a median follow-up of 2.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, the vorapaxar group had significantly higher risks of moderate or severe bleeding (3.4 versus 2.1 percent). There was a possible, but non-significant, increase in risk of intracranial hemorrhage (0.6 versus 0.4 percent). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611365689\">",
"    <span class=\"h3\">",
"     Anticoagulant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with cardiovascular disease, we do not recommend anticoagulant therapy if they are taking recommended antiplatelet therapy. There is some evidence that anticoagulant therapy is better than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the prevention of ischemic heart disease events. For instance, in a 2003 meta-analysis of six trials (4155 patients with coronary artery disease), when compared to aspirin alone, those assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (international normalized ratio &lt;2.0) had a significant reduction in the risk of death, MI, or stroke (13.5 versus 16.3 percent; odds ratio 0.79, 95% CI 0.67-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/75\">",
"     75",
"    </a>",
"    ]. However, they also experienced a 2.1 fold increase in major bleeding. &nbsp;",
"   </p>",
"   <p>",
"    Long-term anticoagulation added to antiplatelet therapy may improve ischemic heart disease outcomes in some patients with coronary heart disease, but increases risk of major bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link&amp;anchor=H8#H8\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Rates'",
"    </a>",
"    .) For instance,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    may be of benefit in patients with an acute coronary syndrome who are treated with dual antiplatelet therapy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=see_link&amp;anchor=H3770019#H3770019\">",
"     \"Chronic anticoagulation after acute coronary syndromes\", section on 'Rivaroxaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several high risk conditions for which the simultaneous use of chronic oral anticoagulation and dual antiplatelet therapy, which is referred to as triple oral antithrombotic therapy (TOAT) is indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular (LV) thrombus or aneurysm. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=see_link\">",
"       \"Left ventricular thrombus after acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25673?source=see_link\">",
"       \"Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Left ventricular ejection fraction (LVEF) below 30 percent with or without heart failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=see_link&amp;anchor=H1015181#H1015181\">",
"       \"Indications for antithrombotic therapy in heart failure\", section on 'Antithrombotic therapy compared to placebo'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=see_link&amp;anchor=H5#H5\">",
"       \"Supraventricular arrhythmias after myocardial infarction\", section on 'Atrial fibrillation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prosthetic heart valves. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"       \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prevention or treatment of venous thromboembolism, such as deep vein thrombosis and pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link\">",
"       \"Anticoagulation in acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link\">",
"       \"Treatment of lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients",
"    <strong>",
"     with peripheral artery disease",
"    </strong>",
"    , the WAVE trial evaluated the potential benefit of adding an oral anticoagulant (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    ) to antiplatelet therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/76\">",
"     76",
"    </a>",
"    ]. In WAVE, 2161 patients were randomly assigned to either antiplatelet therapy (92 percent on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) alone or with anticoagulant therapy (target INR 2.0 to 3.0). After a mean follow-up of 35 months, there was no significant difference in the combined primary endpoint of MI, stroke, or cardiovascular death (12.2 versus 13.3 percent with antiplatelet therapy alone, relative risk 0.92, 95% CI 0.73-1.16). There was, however, a significantly higher risk of life-threatening bleeding in the combined therapy group (4 versus 1.2 percent; relative risk 3.4; 95% CI 1.84-6.35).",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in the secondary prevention of",
"    <strong>",
"     stroke",
"    </strong>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers decrease mortality and, unless contraindicated, should be part of routine therapy in patients with an acute MI or heart failure due to systolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/2\">",
"     2",
"    </a>",
"    ]. Low doses are generally recommended initially in patients with heart failure to minimize the risk of an acute worsening of cardiac function. The evidence supporting these recommendations is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hypothesis that beta blockers decrease mortality in patients with stable angina",
"    <span class=\"nowrap\">",
"     pectoris/coronary",
"    </span>",
"    artery disease and no prior myocardial infarction has not been tested in randomized trials. In the international REACH registry of patients with established cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/77\">",
"     77",
"    </a>",
"    ], patients were enrolled in 2003 and 2004 and followed prospectively for up to four years. The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke. Propensity score matching identified 3599 pairs of patients with and without beta blocker use after MI.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    use was 70 percent and statin use 75 percent. After a median follow-up of 44 months, there was no significant difference in the primary outcome (12.9 versus 13.6 percent, respectively; hazard ratio 0.92, 95% CI 0.79-1.08).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     ACE inhibitors or ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) decrease cardiovascular mortality in post MI patients with systolic dysfunction and ACE inhibitors in most patients with an acute anterior MI. ACE inhibitors and ARBs also slow the rate of progression of proteinuric chronic renal failure, which is more common in diabetics post MI. In addition to their efficacy as monotherapy, the combination of ACE inhibitors and ARBs provide greater benefit in selected patients with systolic heart failure or proteinuric chronic renal failure.",
"   </p>",
"   <p>",
"    The discussion of these issues is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACE inhibitors and ARBs have been hypothesized to have cardioprotective effects independent of blood pressure lowering in patients at high risk for a cardiovascular event. However, the available evidence suggests that the attained blood pressure is of primary importance. ACE inhibitors or ARBs may be a first-line drug of choice to control blood pressure in diabetic and metabolic syndrome patients with and without prior MI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subgroup analyses of major CVD trials led to the formulation of the hypothesis that ACE inhibitors and ARBs reduced the rate of new onset type 2 diabetes by about 25 percent. This finding, however, was not observed in DREAM, a randomized trial designed to test this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H30#H30\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Inhibition of angiotensin II'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5260668\">",
"    <span class=\"h2\">",
"     Aldosterone blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2011",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    guideline on secondary preventions, which recommends aldosterone blockade for post-myocardial infarction patients without significant renal dysfunction or hyperkalemia who are receiving therapeutic doses of an ACE inhibitor and a beta blocker and who have a left ventricular ejection fraction &le;40 percent, and who have either diabetes or heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Influenza vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with established CVD and high-risk primary prevention subjects with multiple risk factors may have increased risks for complications of influenza infection. In population-based cohort studies, such individuals who self-select for influenza vaccination experience a significant reduction in cardiovascular events. In three small randomized trials of 200, 658, and 439 patients, those assigned to influenza vaccination had decreased risks of CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the 2011",
"    <span class=\"nowrap\">",
"     AHA/ACCF",
"    </span>",
"    guideline on secondary prevention, which recommends that all patients with cardiovascular disease should receive an annual influenza vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Fish oil and marine omega-3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of fish oil and marine omega-3 fatty acids in the primary and secondary prevention of CVD is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063335928\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic research suggested potential benefits and observational epidemiologic studies indicated that patients prescribed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    had improved cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. The LoDoCo trial randomly assigned 532 patients with stable coronary disease and taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and a statin to colchicine 0.5 mg daily or no colchicine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/85\">",
"     85",
"    </a>",
"    ]. After a median follow-up of three years, patients assigned at random to colchicine had a large and significantly lower incidence of the primary endpoint (a composite of acute coronary syndrome, out of hospital cardiac arrest, or non-cardioembolic ischemic stroke) (5.3 versus 16.0 percent; hazard ratio 0.33, 95% CI 0.18-0.59). The relatively small sample size and open-label design without placebo control as well as a far larger than expected effect size suggest the need for more conclusive evidence before colchicine is prescribed for secondary prevention of cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Drug therapies with unproven benefits",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Antioxidant vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antioxidant vitamins, which are nonprescription and sold over the counter have promising basic research and supportive observational data, but the randomized evidence has not demonstrated clinical benefits on CVD in secondary or primary prevention.",
"   </p>",
"   <p>",
"    The hypothesis that vitamin E,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin C decrease the risks of CVD has been tested in several large scale randomized trials in secondary and primary prevention. The results have not supported either the potential beneficial mechanisms suggested from basic research or possible benefits hypothesized from observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/86-89\">",
"     86-89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Homocysteine and folic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although in observational studies, subjects with elevated levels of homocysteine have an increased risk of CHD, and the fact that vitamin supplementation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    lowers homocysteine levels, data from multiple randomized trials designed to test the hypothesis show no significant benefits of folic acid supplementation on the risks of CVD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of homocysteine\", section on 'Secondary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90041273\">",
"    <span class=\"h3\">",
"     Postmenopausal hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between postmenopausal hormone therapy and cardiovascular risk is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/37/36435?source=see_link\">",
"       \"Patient information: Medicines after an ischemic stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=see_link\">",
"       \"Patient information: Exercise (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"       \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=see_link\">",
"       \"Patient information: Risks and benefits of alcohol (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28642?source=see_link\">",
"       \"Patient information: Diet and health (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with established coronary heart disease (CHD) have high risks of subsequent cardiovascular events, including myocardial infarction (MI), stroke, and death from cardiovascular disease (CVD). In addition many primary-prevention patients with multiple risk factors also have similarly high risks of these CVD events. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Patients with coronary heart disease risk equivalents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Therapeutic lifestyle changes that include the identification and treatment of multiple major modifiable risk factors for CHD (dyslipidemia, hypertension, smoking, obesity, physical inactivity, and diabetes) reduce the risk of future CVD events and benefits are additive. Thus, healthcare providers should exert all reasonable efforts to achieve decreasing weight, smoking cessation, increased physical activity, and adoption of a healthy diet in all patients with established CHD. For virtually all such patients, however, adjunctive drug therapies will be necessary, so healthcare providers should measure and treat blood pressure, lipids (including total and HDL cholesterol and triglycerides), and fasting blood sugar. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Established risk factors for atherosclerotic CVD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link&amp;anchor=H3#H3\">",
"     \"Screening for diabetes mellitus\", section on 'Type 2 diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic lifestyle changes will decrease morbidity and mortality in patients with CHD or CHD risk equivalent. Based on the totality of evidence intensive risk factor modification has been recommended by many major organizations for all patients with CHD and those with a CHD risk equivalent. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Adjunctive drug therapies are of proven benefit in many of these patients and they include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , statins, beta blockers and ACE inhibitors or angiotensin receptor blockers. These drugs may provide beneficial effects on risks of CVD through mechanisms that may or may not be directly linked to the risk factors discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/60/40906/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Other therapies'",
"    </a>",
"    above.)&nbsp;",
"   </p>",
"   <p>",
"    No single intervention for any risk factor nor interventions on multiple risk factors reduce the risk to &ldquo;zero&rdquo;. Thus, all therapeutic lifestyle changes and adjunctive drug therapies&nbsp;of lifesaving benefit should be utilized to minimize the high absolute risk for subsequent events of patients with established CHD. (See",
"    <a class=\"local\" href=\"#H184471343\">",
"     'Residual risk'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/1\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/2\">",
"      AHA, ACC, National Heart, Lung, and Blood Institute, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/3\">",
"      American Diabetes Association. Standards of medical care in diabetes--2007. Diabetes Care 2007; 30 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/4\">",
"      Witt BJ, Brown RD Jr, Jacobsen SJ, et al. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med 2005; 143:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/5\">",
"      Witt BJ, Ballman KV, Brown RD Jr, et al. The incidence of stroke after myocardial infarction: a meta-analysis. Am J Med 2006; 119:354.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/6\">",
"      Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/7\">",
"      Eidelman RS, Lamas GA, Hennekens CH. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med 2002; 162:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/8\">",
"      Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/9\">",
"      Haffner SM, Lehto S, R&ouml;nnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/10\">",
"      Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010; 304:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/11\">",
"      Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/12\">",
"      Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/13\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     Antman, EM, Hand, M, Armstrong, PW, et al. 2007 focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2008; 51:XXX. Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007).1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/16\">",
"      Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/17\">",
"      Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008; 118:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/18\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/19\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/20\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/21\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/22\">",
"      Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/23\">",
"      LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/24\">",
"      Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998; 128:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/25\">",
"      Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/26\">",
"      Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/27\">",
"      Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 2012; 125:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/28\">",
"      Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/29\">",
"      LaRosa JC, Deedwania PC, Shepherd J, et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 2010; 105:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/30\">",
"      Tikkanen MJ, Szarek M, Fayyad R, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol 2009; 54:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/31\">",
"      Murphy SA, Cannon CP, Wiviott SD, et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009; 54:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/32\">",
"      Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/33\">",
"      Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/34\">",
"      Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006; 114:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/35\">",
"      Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/36\">",
"      Hennekens CH, Hollar D, Eidelman RS, Agatston AS. Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. MedGenMed 2006; 8:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/37\">",
"      Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/38\">",
"      Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/39\">",
"      Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/40\">",
"      Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001; 103:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/41\">",
"      Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/42\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/43\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/44\">",
"      Pastor-Barriuso R, Banegas JR, Dami&aacute;n J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/45\">",
"      Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/46\">",
"      Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153:578.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/48\">",
"      Iestra JA, Kromhout D, van der Schouw YT, et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation 2005; 112:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/49\">",
"      Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/50\">",
"      Rea TD, Heckbert SR, Kaplan RC, et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002; 137:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/51\">",
"      Krauss RM, Winston M, Fletcher RN, Grundy SM. Obesity: impact of cardiovascular disease. Circulation 1998; 98:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/52\">",
"      Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995; 273:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/53\">",
"      Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/54\">",
"      Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/55\">",
"      Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/56\">",
"      van Dam RM, Rimm EB, Willett WC, et al. Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med 2002; 136:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/57\">",
"      Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/58\">",
"      Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005; 143:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/59\">",
"      Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/60\">",
"      Muntwyler J, Hennekens CH, Buring JE, Gaziano JM. Mortality and light to moderate alcohol consumption after myocardial infarction. Lancet 1998; 352:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/61\">",
"      Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/62\">",
"      Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/63\">",
"      Estruch R, Ros E, Salas-Salvad&oacute; J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/64\">",
"      Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/65\">",
"      Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010; 303:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/66\">",
"      Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011; 64:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/67\">",
"      Dehghan M, Mente A, Teo KK, et al. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation 2012; 126:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/68\">",
"      Lau HL, Kwong JS, Yeung F, et al. Yoga for secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2012; 12:CD009506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/69\">",
"      Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/70\">",
"      Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/71\">",
"      Malmberg K, Norhammar A, Wedel H, Ryd&eacute;n L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/72\">",
"      Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/73\">",
"      Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/74\">",
"      Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2&deg;P-TIMI 50 trial. Lancet 2012; 380:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/75\">",
"      Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003; 41:62S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/76\">",
"      Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/77\">",
"      Bangalore S, Steg G, Deedwania P, et al. &beta;-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/78\">",
"      DREAM Trial Investigators, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/79\">",
"      Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 2004; 25:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/80\">",
"      Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000; 102:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/81\">",
"      Phrommintikul A, Kuanprasert S, Wongcharoen W, et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011; 32:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/82\">",
"      Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol 2012; 39:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/83\">",
"      Langevitz P, Livneh A, Neumann L, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 2001; 3:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/84\">",
"      Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol 2007; 99:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/85\">",
"      Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/86\">",
"      Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/87\">",
"      Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/88\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/89\">",
"      Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 2007; 167:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/90\">",
"      Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/60/40906/abstract/91\">",
"      Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med 2006; 354:1744.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1505 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40906=[""].join("\n");
var outline_f39_60_40906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H49\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Patients with coronary heart disease risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14525374\">",
"      - Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Noncoronary atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Multiple risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H282986510\">",
"      PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LIPID MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184471343\">",
"      Residual risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Recurrent events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Possible role of CRP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - HDL-cholesterol and triglycerides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CONTROL OF HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Therapeutic lifestyle changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Choice of antihypertensive drug",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      THERAPEUTIC LIFESTYLE CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cardiac rehabilitation programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Weight reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Alcohol drinking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81267106\">",
"      Yoga",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      After acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      METABOLIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      GLYCEMIC CONTROL IN DIABETES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H611365682\">",
"      - Antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H870617049\">",
"      Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H870616861\">",
"      Vorapaxar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H611365689\">",
"      - Anticoagulant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      ACE inhibitors or ARBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5260668\">",
"      Aldosterone blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Influenza vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1063335928\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Drug therapies with unproven benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Antioxidant vitamins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Homocysteine and folic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90041273\">",
"      - Postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1505\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1505|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/1/34845\" title=\"figure 1\">",
"      Diabetes increases coronary mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/19/317\" title=\"figure 2A\">",
"      Increasing plasma cholesterol and coronary risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/19/34109\" title=\"figure 2B\">",
"      Plasma cholesterol and cardiovascular mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/47/7933\" title=\"figure 3\">",
"      Short-term effects of MI on blood lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/61/20447\" title=\"figure 4A\">",
"      CHD mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/18/12591\" title=\"figure 4B\">",
"      Stroke mortality related to BP and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/40/43662\" title=\"figure 5\">",
"      CV risk and BP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/34/25133\" title=\"figure 6\">",
"      Weight loss and fall in BP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1505|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/61/10206\" title=\"table 1A\">",
"      Framingham ATPIII score men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/17/8478\" title=\"table 1B\">",
"      Framingham ATPIII score women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/56/11147\" title=\"table 2\">",
"      NCEP very high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/16/41227\" title=\"table 3\">",
"      Therapeutic lifestyle diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/4/11340\" title=\"table 4\">",
"      ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/46/2795\" title=\"table 5\">",
"      Non HDL cholesterol goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/41/35484\" title=\"table 6\">",
"      Classification and management of blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/24/43403\" title=\"table 7\">",
"      Lifestyle modifications in HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/53/11101\" title=\"table 8\">",
"      Treatment of HTN by underlying disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/13/20699\" title=\"table 9\">",
"      Rating of perceived exertion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=related_link\">",
"      Chronic anticoagulation after acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13977?source=related_link\">",
"      Efficacy of cardiac rehabilitation in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44567?source=related_link\">",
"      Glycemic control for acute myocardial infarction in patients with and without diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25673?source=related_link\">",
"      Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31222?source=related_link\">",
"      Measurement of serum lipids and lipoproteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3641?source=related_link\">",
"      Obesity, weight reduction, and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=related_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28642?source=related_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/37/36435?source=related_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=related_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44677?source=related_link\">",
"      Prehypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_60_40907="Distribution of GSD";
var content_f39_60_40907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of most common causes of glycogen storage disease among 1438 patients from the United States and Europe",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Enzyme",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of total",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Liver glycogenoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type I",
"       </td>",
"       <td>",
"        Glucose-6-phosphatase system",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type III",
"       </td>",
"       <td>",
"        Glycogen debrancher",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type VI and VIII",
"       </td>",
"       <td>",
"        Liver phosphorylase and phosphorylase b kinase",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type IV",
"       </td>",
"       <td>",
"        Glycogen branching enzyme",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Muscle glycogenoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type II",
"       </td>",
"       <td>",
"        Acid maltase",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type V",
"       </td>",
"       <td>",
"        Muscle phosphorylase",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type VII",
"       </td>",
"       <td>",
"        Phosphofructokinase",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Chen YT. Glycogen storage diseases. In: The metabolic&nbsp;and molecular bases of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), 8th ed, McGraw-Hill, New York, 2001, p.1530.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40907=[""].join("\n");
var outline_f39_60_40907=null;
var title_f39_60_40908="Important immunosuppresive drug interactions";
var content_f39_60_40908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important interactions for immunosuppressive drugs used in cardiac transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Drugs that increase levels of cyclosporine, tacrolimus, and sirolimus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockers",
"       </td>",
"       <td>",
"        <p>",
"         Diltiazem",
"        </p>",
"        <p>",
"         Nifedipine",
"        </p>",
"        <p>",
"         Nicardipine",
"        </p>",
"        <p>",
"         Verapamil",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antifungal drugs",
"       </td>",
"       <td>",
"        <p>",
"         Itraconazole",
"        </p>",
"        <p>",
"         Fluconazole",
"        </p>",
"        <p>",
"         Ketoconazole",
"        </p>",
"        <p>",
"         Voriconazole",
"        </p>",
"        <p>",
"         Psaconazole",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macrolide antibiotics",
"       </td>",
"       <td>",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoroquinolone antibiotics",
"       </td>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV-protease inhibitors",
"       </td>",
"       <td>",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiarrhythmic agents",
"       </td>",
"       <td>",
"        Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal agents",
"       </td>",
"       <td>",
"        Metoclopramide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        Grapefruit juice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Drugs that decrease levels of cyclosporine, tacrolimus, and sirolimus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-tubercular drugs",
"       </td>",
"       <td>",
"        Rifampin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-seizure drugs",
"       </td>",
"       <td>",
"        <p>",
"         Phenytoin",
"        </p>",
"        <p>",
"         Phenobarbital",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal drugs",
"       </td>",
"       <td>",
"        Octreotide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        St. John's wart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Drugs with synergistic nephrotoxicity when used with cyclosporine or tacrolimus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Aminoglycoside antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Amphotericin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Colchicine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Non-steroidal anti-inflammatory agents (NSAIDs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Drugs whose concentrations are increased when used with cyclosporine or tacrolimus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Lovastatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Simvastatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Atorvastatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Ezetimibe",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pham MX, Chen JM, Berry GJ, Rose EA, Schroeder JS. Surgical Treatment of Heart Failure, Cardiac Transplantation, and Mechanical Ventricular Support. In: Hurst's The Heart, 12th ed, V, Fuster R, O'Rourke R, Walsh P, Poole-Wilson (eds). McGraw-Hill, New York 2007. Copyright &copy; 2007 McGraw-Hill Companies Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40908=[""].join("\n");
var outline_f39_60_40908=null;
var title_f39_60_40909="Methods for assessment of macrosomia";
var content_f39_60_40909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61014%7EOBGYN%2F68425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61014%7EOBGYN%2F68425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methods for assessment of macrosomia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Method",
"      </td>",
"      <td class=\"subtitle1\">",
"       Reference",
"      </td>",
"      <td class=\"subtitle1\">",
"       Sensitivity, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Specificity, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       PPV, percent",
"      </td>",
"      <td class=\"subtitle1\">",
"       NPV, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Maternal estimate, parous women &gt;4000 g",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       56",
"      </td>",
"      <td>",
"       94",
"      </td>",
"      <td>",
"       77",
"      </td>",
"      <td>",
"       86",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clinician's estimates &gt;4000 g",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       10 to 43",
"      </td>",
"      <td>",
"       99.0 to 99.8",
"      </td>",
"      <td>",
"       28 to 53",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sonographic estimates",
"      </td>",
"      <td>",
"       1, 3-17",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"6\" rowspan=\"1\">",
"       1. AC",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;4000 g",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       77",
"      </td>",
"      <td class=\"sublist_other\">",
"       75",
"      </td>",
"      <td class=\"sublist_other\">",
"       91",
"      </td>",
"      <td class=\"sublist_other\">",
"       50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;4500 g",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       89",
"      </td>",
"      <td class=\"sublist_other\">",
"       94",
"      </td>",
"      <td class=\"sublist_other\">",
"       93",
"      </td>",
"      <td class=\"sublist_other\">",
"       89",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Serial ACs",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       84",
"      </td>",
"      <td>",
"       94",
"      </td>",
"      <td>",
"       93",
"      </td>",
"      <td>",
"       89",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. FL and AC",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       63",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       68",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. AC and BPD",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       65",
"      </td>",
"      <td>",
"       90",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"6\" rowspan=\"1\">",
"       5. BPD and AC and FL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;4000 g",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       71",
"      </td>",
"      <td class=\"sublist_other\">",
"       92",
"      </td>",
"      <td class=\"sublist_other\">",
"       55",
"      </td>",
"      <td class=\"sublist_other\">",
"       96",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;4500 g",
"      </td>",
"      <td class=\"sublist_other\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist_other\">",
"       22 to 44",
"      </td>",
"      <td class=\"sublist_other\">",
"       99",
"      </td>",
"      <td class=\"sublist_other\">",
"       30 to 44",
"      </td>",
"      <td class=\"sublist_other\">",
"       97 to 99",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       6. BPD and AC and FL",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       86",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       95",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       -",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Adjusted by maternal characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Abdominal wall thickness greater than 11 mm",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       96",
"      </td>",
"      <td>",
"       less than 50",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPV: positive predictive value; NPV: negativepredictive value; AC: abdominal circumference; FL: femur length; BPD:biparietal diameter.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    References",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       1. ACOG Practice Bulletin No.22: Fetal Macrosomia.  2000",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2.  Chauhan, SP, Sullivan, CA, Lutton, TC, et al.  J Perinatol 1995; 15:192.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3.  Chauhan, SP, Hendrix, NW, Magann, EF, et al. Obstet Gynecol 1998; 91:72.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4.  Combs, CA, Rosenn, B, Miodovnik, M, Siddiqi, TA. J Matern Fetal Med 2000; 9:55.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5.  Gilby, JR, Williams, MC, Spellacy, WN. J Reprod Med 2000; 45:936.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6.  Al-Inany, H, Alaa, N, Momtaz, M, Abdel Badii, M. Gynecol Obstet Invest 2001; 51:116.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7.  Pinette, MG, Pan, Y, Pinette, SG, et al.  J Ultrasound Med 1999; 18:813.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8.  Benacerraf, BE, Gelman, R, Frigoletto, FD.  Am J Obstet Gynecol 1988; 159:1118.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9.  Sokol, RJ, Chik, L, Dombrowski, MP, Zador, IE.  Am J Obstet Gynecol 2000; 182:1489.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10. Hirata, GI, Medearis, AL, Horenstein, J, et al.  Am J Obstet Gynecol 1990; 162:238.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11. Owen, P, Ogston, S.  Ultrasound Obstet Gynecol 1998; 11:110.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12. Shields, LE, Huff, RW, Jackson, GM, et al.  J Ultrasound Med 1993; 12:271.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13. Crane, JP, Kopta, MM, Welt, SI, Sauvage, JP.  Obstet Gynecol 1977; 50:205.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       14. Hedriana, HL, Moore, TR.  Am J Obstet Gynecol 1994; 170:1600.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15. Petrikovsky, BM, Oleschuk, C, Lesser, M, et al. J Clin Ultrasound 1997; 25:378.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       16. Gonen, R, Spiegel, D, Abend, M.  Obstet Gynecol 1996; 88:526.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       17. Henrichs, C, Magann, EF, Brantley, KL, et al.  J Reprod Med 2003; 48:339.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40909=[""].join("\n");
var outline_f39_60_40909=null;
var title_f39_60_40910="Goiter CXR";
var content_f39_60_40910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extrinsic tracheal compression caused by a giant intrathoracic goiter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 271px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEPASsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5dAp2OO9OC04LTERjkZxTsZFO244pdpzQA0D0pcHgZ4p4UY5zmnBc0gGbf/10qj/OaeF9qeq9KAJIgSR2rUs1JYCqdsueCK17OL51OOvFAHQ6LgEBjzXa6YRtHPTHTrXFacpDg9OMYrqtNk2AZPHvQhM7HTyAOTx7Vu2pUgYJ/GuSsrjkYPPoTW9bXGOBjJ/WqEdFDO0bgLJg9c9RWxHPvjzs6jFcxDcbhuJ5HTNX4ZW2ZU8k8+tAGhLOiPjrxyafBOGHAz/Kse4IU5IwD15qxp90ERVUfxdfUUAaclwoypx6iqNw0Up+YgHoFApObi9VFX73IrUfToFjJmQHcMZ/rmgDkNT2oCW6+tcrqEyksvftWxrk7K8iA7tpIz61yt5IWB4+lAGVqEm4HkE1zd6u9/UVu3ZJz61k3IG7kUAYF0nNZ8sXGeordmhyfQetU54DnBFSM5+8TbGhwQCT/SqhAxmt6/sZZYYhBE0jKxLYI4HFUP7Mvcc27fmKBlDHJpff17VcbT7wc/Z2/MU02F1z+4b8xQIqY5yPSjbjmrZsbjn91/48KaLSb/nmfzFMZXA7mlx/+upxazZzs4PuKDay4xt/UUCK+KCvPerItZj0TPbqKcbSYdY8fiKAKwwe2aM46VMYJB1X9aTypOw/WkxlMRHjjvSeWeDW9Lpsidgw9VNVjbFTyOfcUwMoID7H0oCZ+taTweoOc+lQvEVP3eKAKpX2pwT2qbbnpSqtAEQT1qRI+PapQg79KlRPl9jSAW0XEg71tWcYzk5rNhhxyAc9q6GzBeNGPReDxSAv2agHkHNbFqcY45NZ1suMe9XoTkEHrTQjYspCr5B5rftJ8jk8j1rn7LO336VqQsQAAenamhG/by7+Ce3Fa1tNhRnqO4rmrOZg/UYFa8cpII42+3emBZv7nEqjlgRgACrGkBzuLtsUDPBrK1CQqYgpwSOR7VdspyI8AjJoAv3U81tdpJAVJXkc8GoNU124kRo9oiJGCQcn8KiuJWKckY6f/qrOmkLK2MfUdaAMm9DMCck8dcVj3Kk9eo6itq4lzkKCxPGPes6VGPG3mgDAvIwcGsqaHLAtnr1xXQ3ETBiGGarNAG6Y5oA52WAZIx1qq8PPAwfet6aHa4A6g1WeEE9PegDHaIBT2+lV2j44JHrW29rk9PyqrNa5BxxSAyCGBGKMcHHWrb27c8YP9aZ5DAdR70AUHGc8H61DjrkZFaLW/PAJzVmDSHI3ynYvoaYGQsRcnA/Gpls89s1tJajcEiQsasLYyEYYBfqaAMBLRt3Q9OlSm0IHzce1dHBYR7h50465IWu+0HwFaat4St7+zvY01a6neO0tpyEScIBkKx43c8Z9KAPF7iwkYZVMD1IxUq+G7p1DfuhnnDNzXX69o95pd01nqVrNaXOQTHMMMFPf6cGq0kMTuSOR0yDQC0MW4twrHJ2jtmq0kKMCN6k+4rp9RsgeccViy2/ls2B/9egDMawLcxspHpVSS3IbDLj6itr7MGXcnB9AeaQnJ8udfMHTPcUAYL6flS0XPtVdYME8YPeum+yFfnhffH/eHUfUU6TTxc8phZPXHWgdzmhB04wamjgyQBk+vFbB0943xJ19Kv2+nKoDSbcnovrSC5kQWpHGOtaVpDscLhtp64q20QaTahBA4LYxmrAtioz1xSAfFGMcZx71fhTDBmHA/WobRCxGMketaUNtJK64woHqetOwE1udigBa0YRv25FQ29uEBOQTnqRVvYSRyGB/CgRJvSNxkEc881cEibVxu4FVJIgQp564OakgAPBYjng0wF1INLJBtYj1PoK3dOgjG1nckIvA9a5y6I8/5WIK4HP61sxXKoCruoGMc0AaF/FG8HmKWQdCPesZgyKQHyc+nNW7mfCKA4KHp9arxDccg5XpigCi/O4AYAqAxuz4Ab61pSAhskBQe2Kjd8yjZlv0FAGPNGAx3LuK9sVG8C9AAR16Y/CtaRlDnEYNOIQ43Iq+mcUAc3cWeRuQZHXFUPspDdMV2SR4fb8hH1FJPZBkDeWpz1wOtAHIm1znGRU1naK37powW6gH+L6e9byWUbNhQFz09/aorq1aEgqCGXkUAc9qGjmIkqp2no2On1rKewlLhFj3E56V3kYnnOIWLRt1BGRjuP51cisba3ztBjlYdQM/p2oA4i10lLaMSSqGkJ4HpSzWhkBlmIihHJcnr9BXWXFlEmc+W0h5HPIrJm0K4vHDPJG4U8IJBx9aAMGSY7QtlEYYuhlI+Z/p6U1LXfgvnPck8murtPC94xy8R8sDOFIY/kDWjBooDbHi2gD5ty4J9qAONt7XcwCg7R1JFd5omj6Te+Hol1rxHNZpBIzxWKW5fyicZdSCOTj9KIfDgYCSJsc9COP/ANdWpbIKVVG6HnAoAg+J+lWo8ShtOcPavZwvvLlz0I5JJ546VxRtbQE/N/47XT6lav8A6mDkNkuR2FUzpyDgOMDj7tAGfqNoFYjP5isa40wtlsjGewrtr+KNlRmIAI7d6qpFFFHkHch7tQByP9lPyYI2/lUUukPlWlAhPqx4NdFe3E4wqsg9NvpXO6kxuHw0hfBP0oAgW0hgYlbkBj1AXirEC27sfvM3oDgZqoy7OhGPpxSKu0hlbFAGyFWRdvlBR2wOf1qrJZvDukA3HoD3qWzuBJhXOD61rxIcjkH0oAxIbfA+6elW0iAX5lPPb1rVSySVzztGOfenvaeUys3zDPagClawEgELhB+GavxKNxGGbp04p6xvIVJwFHQdBU4URqSWyfWgBC0cB2+UzN6Z6Unn7m/1bL6YpyRoTyxPf61OsfP7s5zQAiOXGA2T3Bp6ptOT25pywknONpHpSsjGFwTkY4yKAIIg8rEsnXqCOlasS8ANGjYPHFUNJhZpcKxI71qOjDlVP+FADnImTEkakg5DY/SiOMIpwuGPXFDQ3Klcp8pH+c1KiEBg+B9elAFGSNmfn5h2GaY+FQb9qg8+9WWGWJB56Vj6lMqAjdnHU560CM3VtQlUlbcBEHBYcmsC6uZ25Znz6lsVYvpnLssZwvt6Vi3cyqMM2T7c0DNmyu2YDzJFOOPpWzYXew/LNgZri7a42EDGXPPHetK3kkKDcQg68mgD0OyeK7O1iu49GX+taaaO0qkTgBRyD3HvXCaZqSWcitEp3jktmvQ9D1u3v4VMkiwyrwd3SgCqbMQsVjTYc/nWXqdwLfckYDSdz6V1GqDzYCq8EDhx/EK5u6tGCndznnPr7igDnSjysWlY7f4mzUckIcnaoVfY/wA605Lfy02v9Rx1piW4LcZoATSJ7ixlzDJIvPIDdK7yw1SSUKLs28kJHLOuCB9a5KKEJ7kdTVqNmQFAfl9aAO9eC2ntFNq6tAerIvQ1lGyETMQNwwTnNU9DuWt3XByhOGXswrauIhG5aNW2t0JOcg0AcmkJEjybeWPU+lRtZqxLEHJ54FbUlqFLqvQnO09aZ5I7NQBzl1EJDv6Ih69ABXO39wZjtQFYgflXNdRrQEdmIQRuc/OfauZuIP4gT+FAGY5JUrjBzxiqckHsARWqYx15AFMaIZ+bj3NAGM0PqMinxWwkJ44rSmgHUYz6U63gPPagCGC3AGQAQKv2ashGQNvpSxRc/wCz1PvV+CDahZsbm6e1AFyFEZAeiL/D3qQBmONoVe1VViw68nJ5yOMVoWjldof5Qe4oAZ9iD/NjafU0SWD7WyAR6g1oqELLggj29akQDOefpQBjQ2rgEED3yakW1cehYDBIrZZAGyV/SjbGf4FyDxxzQBleW+7HoM8809oz5bHHHpWoEGSAF9elI0IZGBAx9KAKGl24QM64yex6itFSFfqRTbNMHbwCOeakliYZxyfagB8g+9u4xzmoXUMgAGPX3pQkroAI+nGT3pJtywPnt3oAy72UQqVUZOOxrmbySSaQ4GF7YremHmO2epBIJ9KzTKImOGxzz6GgRhyWczqVCZPftmsqXSpHly5RFHUA10t5dkj/AFuBn15NY1xcRYGwMwPfpk0DKQiSI/uyBjjI606IbmJLn2yKgnvEUgsgUDuTmqsurY+WGNQDwSefxoEbSzwQ5MzszHoijn8fartpdvIufM2rnO3H865VLgs4OF568VejvmBA2IeeO1Az1LQNWdQsbuskXueR9K6E2qSjaAfLflfUV5RpmqpG4yrKPrkV6T4O1WO8RoPMEgPKqeooAjurBkyrKDjgGqMdth8FeK7G+tw8IkUZC/eHfFYkkBWTOQR0FAFXyPl4FKIMH5hnA5rUgVAh3Hn2HSlEIZjyMnnFAEVggQ89O1dNbostvsY84+X61gQIA546H8K3bbmH1xjkUDRWmt2ABCjd3qu9udx+U1rxyxysRMCrdMgdfwqUxwKcZI/KgLHl2q/vHLY+mayZVymAAMH862rtMg4GccjNZUyg9OKBFLy+OlRlSBwMirwjXacAnHtULqMHvQBSKlsAev1qxChUnNPijzztq7axAuGdfp70AMjtwCA6/wC0R6VORj5n45wB6U9/kBA5c8fSnpEfvE7ee/FAEZ3nG3AFSRoW45JqdIlyPlJzzzVpYj/Fx7UAQwRshH8P41dhBJ5Iz6VEoBHDd+lTooAzgnJ6UATLECvGCDzxTWiYDPBNODKeGyAfanDk/e+lAEaq4xkcdcVJ/DggCpVJBOPyoKFue1AECptfcowferA24yGORSbQy8dfrVeOXZIVfJzQBb25Q5Py8Vn6k2xBuGBkk8VoI2U549cVQ1RS1sdi4NAjn7u5SFQSR97PToKwbp3lfgHAyDitO+hySxGSPU8ViyyNGcZ47jrQAx4li+acqOOB1J/wrGvrrH3AiA8DPNS6pdZPJAPsaxZriERHeN5JyOeBQBHMWkO9nBbHJqsEOCxK4phuw2VVV29smk8/CbdqE9c0DNGKN2hP3CB71JHG5yoAJ7c1XNwBDGuzBxluakS4AwFDcnkCgDSjVwFAGT6ZroNAuJbS6iliLJIjA5FcslxHx8zKevNbukz5mjKsHA64POPpQB7lo2oLqdpu4WYAqwUfrVa5h2rvwCrcYHY1geD71VuT1Qngnp9K6+5hbB2Y2OuV470AYgUlh2xzmp0Q4HHNN5EgYAg9CKsJlgT3z6UASeRhgQODjmtOzIVcEgjrWdExLDr1rTjRfK5GB0oGhiAyTlz0B4wKbLdlZGXzOh9KduMaMwPQZxWI02SS2cnmgZzd0ODngD0rKcZyDzzWxcDIPOfX6VmyL8/OPegkgVCB2w3Wq8yEAbRznAzVw4AyT3qMAM3oBzigCOJNxCADA9qvRhiGYY7D6UltGMvjr0q1sUDCjCKKAIUQgKFHOeSalBCrjqfSmk7gAMhR6daljiOwHHWgB8QJIK4Bz2pwU565PvUkcY+XjOKsIoxwP0oAhjXgVIFPf+VOKAZ46+9IpKsM5z6UAToSBjoT14pdnrT4iGHTBqQOMYKnI4xQBEhKZx1755p5cEHrz2qV41KgDgnjiojDgEZoAVAGxt61Rv0MZDDjNXUGJFBz7cVFexBk3HOaAG28zSIMkbx3Hem3KmSNx1NQ2K7ZsHIGKuBQckg+nPFAHM3FnNJuEaFmPBycCsG50O9Zm3Soo7BRmvQxFjKjoefrVe4ijRcuOcdKBHiuuafc2T/OoZR1I5x9a5maUuTgYXOBXsWoWgkLSEDJ615x4n037NMZoARGx+YAcA+tAHP87gMH8alRHZwMHrimoS4yCMjr9KtRskUZO75j0oGTXETRyrwCpHY5xSAvswhXnqPaq5mz/HwO5FOjcEAnhf50AWkVw3C5xzV+yYqwYEqKqxSAsFUhW9GNatvnAK5bIwe9AHW+GNVkt5QSfMTuG7fjXs2j3Ed9pEE8R3Rn5TnqDXhOnspIDKBk84616x4CcxxPATujcDj0PrQCL15AUlcd89fUUzGFQDGepzWnfoGYMRkg7W+lZ7ADnB+lAD1GCCTx71aR/wB1uBGKpIQSCAanyNuCeD+tA0SeZiGU7hnBrH3Adx+VXp5FjgkJwQBjFYP7xjkBhQDKkyjkcdcVnyAAE4HHQCr1wfUnI7VUZeCOfrQIqORsxxj2pY8LH2yeTTgpY8AfhUiR75VGMDqRQBPAhEUadC3JNNbdLM4X7ikfjVlRuTOPYGlRAGPYUACR4zn1qbaQeo4ojIJwvX1NNfCnPfpQBMhGeB+JpHmIPHboAKjDnd1HtQVLKMAnnmgBrOTgZNNU8jnineWxPPT+tHlHNAE8AbPB5q4hODjv61VgBzgY+tXEBXgg4oAeGHoQfapgc9PSodp64I/HrUkancMZ9PSgB+P3gxjP86hu48phRjnrnirKZU4564pLgfJjAJxjNAGfa27CVSCCMVbliG5fm4HpSQLh17Y6VKzEMw7igCEkLwnWs+9PLHr6e9X5WYZYcdz2rLnyWJNAGRdY8sgL+dcf4nsxLAw53enY13F0VRCxxj1rjtbYyHK42knNNCPN1jEV0yMDwMbcUTRgYyCAR0Pc1r39gz3JII3AZyKqvCr/AOtkwyDHSkMzUhaTnjA6+1KrBSDnGOBUoQrGxyBnimxIpPzLkUALGcsSTlq0rdmBBU44xwaqxpGBjbtJ6Y61etIYySQ549qANvTryRZV3sHAx14P516p4Ovopyqq+yTjKnr+fevJLWHe4KsAfToa6vSJXtzlgykdDmgD3K5RpbfcB85XJHrWT/rQMEZq74buzf6LE0nMqDBPc4qK6g8qbcuFV+cY796B2KiggkEYxT8ALz3qV0DDgEDrxTH5TJ6jgYoAy9TJEO0c7iKpbT2/U1ZvAwlB+8PrUP8AwAH3oEzKd9x5wPeqk55xn8KmbnnHWoypLZI9+KAI0XCnH0xU8CE7iPpz60kaZY579hVu1Tajtg8cY9KAHBeFXoqgk1FJ8x+U/L/OppflCKB1GTSxxZAJBAoARflHBGaa65GSeKmK9cAYz2oYBUJJ9/egCvgD2qVc54zg1HvIOF6e9Dg4HJ4oAlPfJHrikwvTcAMVGDgjjA7DvSscjIGD7igC0mBxuHFWY2GcA1RiXK4INTxgYBXOaANCJu3IP0qdF3E9cVVhboDk1aVgO/sDQBI0ZPK5PaoZcFgAeg5z2qeN8DGefaoHYM5OMgmgCIAAjGSM0+RDuHHHrT4FAkAzz6GppY8AY6d/egCjOCI/X8KzJ+DnP0Faty2UwuM9M5rHvSRGScDigDC1FjMHUdAOB6muN1EyLIUIPHIxXWXMmCxwM1lz2bXDB9nf8aBGDNAqWivhixGSMYrmr5lWfdsyvfJ/Wu+ltJpEKSIfLHVuorltato1RvLwzknApgcrLKryHCjHbtnFSpOwUkqMCqzqycEcg05W2j+lIZchdGAZ2wfrV+GeJVBG4DpzyKyEO847deKswnLfKO/5UAdXYBZEVtysW6BTzXSWDFPkJ57qa4W2chxhvoc4I9q6DTtQnWRBJmRe4brigR7r4IVVt0CFhk/d/wAK3L2MGNsEZQ8GuX8DXkdxDD5JAZeSp612d+gCs4HDDBGelBXQwyAnAOM9DVe6+XJxz6VZlBKjdz9KpXiErknIx60AZFw5Y7hz26VCF46/rU8h+uc96ZvA4BwPTFAjFlO3p+XrTIjuOMEVPONx4GBnioxHtIwfagCVVCkA/WrUA/cY5+Zqrgsy7iBn6VbtVYsi+35UAIyBpxIR8o4FSvhfY+tOYAIWIAUdKrF2kb27CgAZtpOPXrUfU9e/XrUxQFcfw9ajbgYB7UAQlRkg96VuoxnmpEXjDAZPQ0roNhwQfWgCIMAwB+bHGfSkI+bDZwfzqZRggkAY4x7U6TCyKdwJoAIgT649KuQgccc46GmpgxBsLn0x2qRWGQBjFAEiMQwGOakdxzk5pqYyCMfjUNzKIwwUDd9elAEqzGLqeTxg1NFIGXn681imXzWC7skdx2rRsmPmbQcgjrQBMH2yAjPX1q6ZA0QOOQKglhC5xzzT41Pl57Y9KAKjZBII6+tZ13FuPIYj+da8ityGwD71HMgP8IHrmgDitUtvLcNyBnrU0FqVTcuQhxyeK3b61VkOMFux64rIaZ48pJgAnigRBewhIWERJyp3KP4hXGXNlbG5IdDt6YJ6V1t5cNAjnYSB09D+Ncjf3Cwl5DGplY5Iz0oA53xDp0MTGeFTj+6TWBHH/E3A+ldVqszz2ZYhQQOuO1c9vy2WH4e9AxFQgDbxkelXIkIKKE4HUnvUQlkRWddik1NFeuke1ipDevBIoAsxRgncRwx45rY05PMlTa3A6Z5/WsmC5DPhlJHY9QK29LaJpRtcE+/BoA9B8PyTWb2s0RIKsv3fTPSvZ2KXNujqPkmj3Y9DivF9AmP2iFVPfI7Zr2LTCJdKTHDIPSgaMho/bkcEVUlGFIIP07VrXUWLhjjAIz+NVZIjjGB1xQM5O+jYNnOOfXpVJo3YkhWI9cmum1K1UoCOMdazBABwc5oJMh1+cgg//XpVQlskZH8qmaMk9ePT0qVEz0yPY0AVynXjII9KuWqj5ePmYbaideuOlWYgUKZ42jpQBXuzn5ONq8VBCvzEDGf0pssqrKd5xzzVkMFIGRyOMUAKqgDk5PaopRlSf0qRmJHb6moHlC7dgx2yaAG47g0hkAXHrwfeoHY7iST9KidxkYPy+/agCyGIAbgDtzUHmhmbkAg+lR+ZucYKgj+VUpXKuxAyxOMeooA3YLkMu7PyjgD1pwuWD7T0H61h29wC4YHhfl21aaZlUsQBigDVn1ALEFjX5+xJ6VmzXBdzuJJPU9l+lMhl+2PgcAdCKVrfYeOSemBQBasVBf5eQDXS2UEQRSw5PTHGDXPaekitkYBPbFdHayfcG3vjigC06ApjB9KUQ5XGCO/WnSHPTmnwg4wTjtzQBTmtySMY/Cqs6HZzkZ45rYKZXHPNQXEO5SSM0AcpcsUc4PTueprHntHnuA7jKDnBOAa6u9sgzMTk8dfSs+W1VlKfMCf4hQBmXE1pMjKse9gMH0zXBeINNlWbIYbWPHsPSu1utLubbf5KFkc5x/Wub1FSqgShyQe4oEc2IAY3gkPmbRn6Vyt0pS4YN0612s0UMhZY32k9TkVganYPAGC/OCeD7UAYgyzn5jipYmUD5sk5xTnh2Lg4LntTlGUVeBg0DLMDoCVOFweoFbGmBGcFflXHesNFJYYTp3HNbumxhIyzlgevTt6UAdj4UuXhvkAYFRj5T0P+Fe2eE9QS4RojlWbjaT0rw7wwVjeNs4ZnzyOa9L8NylZiVOGHIOfegEd9fw/KHwCy8H3rPePgbh+NbhYXNqkoGMjDYrOePaWRxnHFIozLqPMXB6VjPEQx5I5rfuYzx0IFUWjbJwEx7imJo5cpkkgHANOUBlyBk1LtG4g+tPAwM/jSArmPKjg8nHFWNmVY4OBSqAzAHnmp3UiA5HJ7kUxHIas5W5fnAH8qzbLVD9sEAw3HB9Par/iHBb5U+UHtxmucwLe5iuADhD81AHZLIWAOfz70jN8rY4PpVO2uNyBgSVI4OKk3g9yc8Z9KAFlYKAe9U3mAcE8j86n81FyD909c1DPtAIXG3qBQBAZGBBGcE4qldNKrYX5gPmNTsxxu3Dg/TFRXF3F5oU5U4B+tAEOkzrIZ4WO1icqSefpVxUlk2ZLEA85rFkQw3e9eApzwO1drpdt9qRLiNsIw3cjg0AS2lq0UYxgDr0qf7LLKcjn19qleVt4UcDpirFmrNIVUEZ4JoAsaZaYGT16VqQwbXyRwPX1qWwQKOB9M1e2ngqvP0oAqhCWHPFTxR4PQGkKsTgkVYhiPbHSgBgTPYUNEMHPI6g1P5ZXPPf8AKjapwDzigZnXNqGjJAOffvWb9gaNgSSK6Vhx8wBFU5498eB0PtigRkNAHOMAj37Vn6ro9peWrxyxIOOCOta0to24Eg8VOsY2ruXmgDxzXfCUltvaBw6dsnpXKXsTwfI6jeB0bjGK+hr2wWWNwEX5uCPWvPPFXh3MDZiLdcEDmgDyW38qR91yBhyQDj+VQyLBFIyqG9M/1p+oafLDv8xHCg/fxjAoRFEQZm3f7XUUAXbK3jK+ZkAqfungt7ithWc7QEUJ0rJtEi8pmNwd5wF44rTspWVsnDd8npQB1ugxIZUZew5yM/lXc6LGolZkJB4yPSuF0W/G0Myc5xwP6V22iTLtymOT2NAHpOjsDb+W/piluowrpJjr8p+tVtHnGUJOckDGK2by3yrnJweR7UijCuVyOn0xVJ0O44TI+taMiYfaTk9s1AUUE5VifXimByWzJPTNKseM4I6VYK7V9c9qHGF6DBoAggTMoz06mnamxjtSQSCTzUtqnU+pxmoNYOYCTjg/pQLoclrQ3QZONprlLmYxNlT26YrrL51bcHwB6f4VyWrAQMd4I3DKnNAiez1fChTiMdMetWP7XjP3SOTXITSMcPE2DnHPWs+W5k3MoJ3+5oA9CbVrV0xKw8zt7VRurl5IlEEv0zXCJFLc5VpdhUbhk9frT7Z5LRjl/NHf5uMUAdLPe3UCEyhivQlvStHTLOacpLKd46jAyQPSs+zu4JghmuFQgdGXIFdx4djjiEZt0WTIwQrZBFAFeHRPNj3yrgDqO5rqLZzHYQW6qqqBjp0pbdZvOkURgRdmJ6VbKFDkqCex/wDrdqAK8dgZGy3HvWlbWvkjjk9/eltVZgCwya0RH2UUAMiGFyM81bic5xnjp7iolTLYPH0qxFHjj16UDQ7Zk571ZhG1QDjNLGnAyetSqmRx1FAxmwkZOPrQYzg9KnVBjIwD3zUnlnaR3oAoEdsZpPJz/wDWq35WSfX0pfKBFAFIxDPHFMktwVyBg/Wr5jxjqc0qJlckfSgSRktAxIIY5qjqNsZIykicY64rozCDkAD/AAqFoVKFWIII70BY8a17SBB53nwJLbuCOnTPrXmGpac+n3QeHKwk5AxkV9M6rpEUpbYQAR0PQ1w2u+Fd6OUUDPABHGaBHi8TqJAQq4HysprYtEKRhwSQ2ckVPqvhq8sbjdJav5bcgr3plrbzNITJ8sfYdOaANywCwwqsa7S3G49T+FdXobDaoDMOc/N/OuZt22gIzBwFAOR0PtXRaem2NG3D5hxjrQB6Lpl2VERYjGQAR6V3cb+dbIRjBHNeV2UqqkfLYOBivQvD1xvgCM2QOme1JjRXuI9km3jj9RULLk8EfjWtfw8lscr/ACrKIwTQhnMBMg46mo3U4C4wKuIvBBxmmtHnBHP40ARwR4VDz3OayvETbYccDPPNdAyFEPzcAY+lcv4hzK+E6jpQJnI3bO/+r6KMnIrGvofPLmX5kVeOep9q3J4JpJPKjUs7dRWppvhVlAkuW3P1AHamI84Gh3V2wABRCcAtVxfBUpmUly4Xrz1r1KLQIlfftZieuTV1NIRBhRgnuDQFjy2DwSqgyOzDd1GetWbXwHBLGx8tlZuMqeCK9Si0pHUbhkH2q6LM4wo4oA8qh+HbxEFpQV781q2Ok3NgAscQVegbP3q9Fe2XyyGGccjFV7iFNuMDHTmgDF0xZWTbKw3DpitTylCg4J49aaqRIhXBUgZ5oiLMMlsg96ALsCfIuVA5yKsquef51RtmddvPTrmtSLBGRmgYLHwOefpUkcYDfN0z607g8j86WNBnvmgZKq46DBqyikoKiAHA/WrUa/KMdCKAGhBmnqvT0qULnmnheuOc0AQBBngdKCOlT7fTNII+BgUAVyM9PxpCmDjPFWAmScDk0oXOMUAVGUjoB1qGYHY2VHNXnUAYAqpIrNwCB/OgDMmQtHjH4VmXTCJWDg4/PBraceQAOSOeRVO6t45V3CgTOS8RW8V1bBim8ry6k4JHciuNfTIASQu5GOFbPzKT2IrtdbgMbsu7Ibjj1rz+KW4tNQmt3jZpFY7cDqKBEpsVMoRcLg5+bvWtawyxOG8oHI/hOeKjtIGvEJAlRuhDdRW5ZaewwyE8DnOeDQIt2lwHZFbAdRtz0Ndx4ek2lOckiuRitPny6ncMfMP610+i5jZBgHikykdbNiWMtnkAqaxmjfccNgenFats+5HBPOKqzwbpWIVufQ4pDOWVPlGccU6KLJyV6cdamVAB0zUsaAAMT7/WgCpegrCw7+lYj2hlOQOg9a3rtPMyASST3ogthswe3pRcDJsNLjjffsG7tWn9m3dF5q4seAMDIqdYz6Y+opgZ6WxB6dutSLbhQOMg+1XvLyRxz70u0DigCosIAJIxzQUP8OAOue9WhH6inrFjnFMDP8onoOAf1qGe3JGQPxrVaMk5zThEdrKAKAMK5st8WOM1TggMZ2np2rpZIQeO2OeKrSWoBJ4z6UCsZiqQBxVqH5Rx0NOa3IOByanigZcE4H40AkGGIxgip4lwo7f1phXsSR74qxCOOQPY+tAwVfccVdgXI2nGP61CseTk9MVahXGMDI70gJFTr/On7CRx3/SpUTjdjjvUoUgjIzQBX29TS7cgD09KnEYJzgU4oPypAVNuPpTSoH1q06fLn05qN0pgU39s+1UpThvX37YrSdW5JUj9aqmPIPGfSmBUuvmiB4Kg596y7psIVU7fYDrXQJayOuD8uaSDTEjk3su9vc0Achc6HPeIkg+Rc557isTVPDksN3HcwAPuG0j37GvVRAO68f54pstgrJgYx3GKBWPOYNGnJDGEru6r3H0rYstLmiTBUAdPmNdcluQQOMY5GKke3O3KYIpXCxz0WlhiMqQp64q7BYeTIpUjB7VorbknJBJ+tSiHEZ3c0DIbYbZPvAluOKlI5PAPvmobTAn2DJye/arDqNxyefpSA5hk6A8j+VPK7QzbcdqdjcwyM1IygrwMZNAFVIQ7b3AbbyvHT6VMsXHHGKsJHjtxT9npx9aAIQmDxUu0/wD1zUoUYPHA6+1PVQCOSQRQBEiA9acY8jnFThOmemacF6mgCusfc9KNpzx9OnSrBXt1o2n0z9KAIPLH50oQADPpU/ljGBTgvencCs0efrUTwj72DmrxH0pjpkEjg/zoApGHg8VDJtiGCCSTxWgU9gBVWRN7hgAFXtTAiC5555qzFHwCOB0pyQg4NWIoyvOOntSAYiA44Iyaswx/PnnniliU9wc1OBx70MCQJg5A5p4HvTlX2p2KQDQuB60jjjPWnmkIyaAISPQfXFIFyRtH0qbHtmlCAHJ607gQCHdnd096cIFBBwMip6KVxkPkjrR5YIHTNTUUARNFnp/+unbOcin0UAQSQjIYD/61KFwB/WpqMDFAECpzgjinvGChUcA1JRQBmzQFZ0cDoeasNt3HipZASDwajBOOP0oA5pRlh6ZqcA+nemIoz16cnAq0i4XPWgREATwFPXvT1T25NSBQMk545p4HQAA/4UAIi5GO/pTlAK8Y9Kei88jn0qXbwcdKAIUHBB5NPC45HSnbeeOKkUEjAzk0ARhcjpRtwfWpgmMkj60hXpkd8UARFcjg8dM0AZXHNS7f8PrSY9TxQAzBxzzTSOCMYqcDOc4NG3kA0AVJVyMDuab5XcDmrjR7uvAoEYzyaYECx9eKljjIxU4jAHHWnsMLjApAQqCAAKlUcd6cF4/lTlH0+tADgKWiigYUmKWigAooooAKKKKACiiigAooooAKKKKACiiigBG6dM1UcZYnGauHpVZlG45AoA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph reveals a large mass in the right hemithorax with displacement and narrowing of the cervical and proximal intrathoracic trachea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40910=[""].join("\n");
var outline_f39_60_40910=null;
var title_f39_60_40911="Air embolism during ERCP";
var content_f39_60_40911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cases of air embolism during ERCP reported in the literature",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Reference/year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age/sex",
"       </td>",
"       <td class=\"subtitle1\">",
"        Underlying disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Endoscopic procedures",
"       </td>",
"       <td class=\"subtitle1\">",
"        Complications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic findings and imaging",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simmons et al, 1988",
"       </td>",
"       <td>",
"        23/F",
"       </td>",
"       <td>",
"        Bile duct stone",
"       </td>",
"       <td>",
"        ES",
"       </td>",
"       <td>",
"        Portal venous gas",
"       </td>",
"       <td>",
"        Radiographs during ERCP",
"       </td>",
"       <td>",
"        Uneventful",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Merine et al, 1989",
"       </td>",
"       <td>",
"        39/F",
"       </td>",
"       <td>",
"        Papillary stenosis",
"       </td>",
"       <td>",
"        ES",
"       </td>",
"       <td>",
"        <p>",
"         Retroperitoneal perforation",
"        </p>",
"        <p>",
"         Pancreatitis",
"        </p>",
"        <p>",
"         Portal venous gas",
"        </p>",
"       </td>",
"       <td>",
"        Abdominal CT",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blind et al, 1991",
"       </td>",
"       <td>",
"        60/M",
"       </td>",
"       <td>",
"        Bile duct stone",
"       </td>",
"       <td>",
"        ES",
"       </td>",
"       <td>",
"        <p>",
"         Moderate bleeding",
"        </p>",
"        <p>",
"         Portal venous gas",
"        </p>",
"       </td>",
"       <td>",
"        Radiographs during ERCP",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barthet et al, 1994",
"       </td>",
"       <td>",
"        31/M",
"       </td>",
"       <td>",
"        Bile duct stenosis",
"       </td>",
"       <td>",
"        ES",
"       </td>",
"       <td>",
"        <p>",
"         Mild bleeding",
"        </p>",
"        <p>",
"         Portal venous gas",
"        </p>",
"       </td>",
"       <td>",
"        Radiographs during ERCP",
"       </td>",
"       <td>",
"        Uneventful",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herman et al, 1995",
"       </td>",
"       <td>",
"        46/M",
"       </td>",
"       <td>",
"        Liver transplant for cirrhosis",
"       </td>",
"       <td>",
"        ES",
"       </td>",
"       <td>",
"        <p>",
"         Moderate bleeding",
"        </p>",
"        <p>",
"         Portal venous gas",
"        </p>",
"       </td>",
"       <td>",
"        Radiographs during ERCP",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tighe et al, 1996",
"       </td>",
"       <td>",
"        31/M",
"       </td>",
"       <td>",
"        Cirrhosis and portal cavernoma",
"       </td>",
"       <td>",
"        <p>",
"         ES",
"        </p>",
"        <p>",
"         Dilatation balloon",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Moderate bleeding",
"        </p>",
"        <p>",
"         Portal venous gas and opacification",
"        </p>",
"       </td>",
"       <td>",
"        Radiographs during ERCP",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kennedy et al, 1997",
"       </td>",
"       <td>",
"        63/F",
"       </td>",
"       <td>",
"        Bile duct stone",
"       </td>",
"       <td>",
"        <p>",
"         ES",
"        </p>",
"        <p>",
"         Stone extraction",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mild bleeding",
"        </p>",
"        <p>",
"         Venous air embolism",
"        </p>",
"        <p>",
"         Cardiorespiratory arrest",
"        </p>",
"       </td>",
"       <td>",
"        Radiographs during ERCP and post mortem",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nayagam et al, 2004",
"       </td>",
"       <td>",
"        56/M",
"       </td>",
"       <td>",
"        Malignant bile duct stenosis",
"       </td>",
"       <td>",
"        Biliary stent",
"       </td>",
"       <td>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Cerebral ischemia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Echocardiography",
"        </p>",
"        <p>",
"         Autopsy",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giuly et al, 2005",
"       </td>",
"       <td>",
"        60/F",
"       </td>",
"       <td>",
"        <p>",
"         Bile duct stenosis",
"        </p>",
"        <p>",
"         Myeloma multiple",
"        </p>",
"       </td>",
"       <td>",
"        Biliary stent",
"       </td>",
"       <td>",
"        <p>",
"         Venous air embolism",
"        </p>",
"        <p>",
"         Hypoxemia and shock",
"        </p>",
"       </td>",
"       <td>",
"        Echocardiography",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Siddiqui et al, 2005",
"       </td>",
"       <td>",
"        43/F",
"       </td>",
"       <td>",
"        <p>",
"         Recent liver biopsy",
"        </p>",
"        <p>",
"         Ampulloma of Vater's papilla",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         ES",
"        </p>",
"        <p>",
"         Brushing and biopsy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Venous air embolism",
"        </p>",
"        <p>",
"         Cardiorespiratory arrest",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Radiographs during ERCP (post mortem review)",
"        </p>",
"        <p>",
"         Autopsy",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mohammedi et al, 2005",
"       </td>",
"       <td>",
"        27/M",
"       </td>",
"       <td>",
"        <p>",
"         Hepatic trauma",
"        </p>",
"        <p>",
"         Biliary fistula",
"        </p>",
"       </td>",
"       <td>",
"        ES",
"       </td>",
"       <td>",
"        <p>",
"         Venous air embolism",
"        </p>",
"        <p>",
"         Hypoxemia and shock",
"        </p>",
"       </td>",
"       <td>",
"        Cardiac auscultation",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stabile et al, 2006",
"       </td>",
"       <td>",
"        65/M",
"       </td>",
"       <td>",
"        <p>",
"         Previous PTBD and ES",
"        </p>",
"        <p>",
"         Biliary colic and icterus",
"        </p>",
"       </td>",
"       <td>",
"        Cholangiography",
"       </td>",
"       <td>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Cerebral ischemia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Abdominal and cerebral CT",
"        </p>",
"        <p>",
"         Autopsy",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rabe et al, 2006",
"       </td>",
"       <td>",
"        87/M",
"       </td>",
"       <td>",
"        <p>",
"         Benign biliary stricture",
"        </p>",
"        <p>",
"         Patent foramen ovale",
"        </p>",
"       </td>",
"       <td>",
"        Disobstruction of metal biliary stent",
"       </td>",
"       <td>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Unconsciousness and hemiparesis",
"        </p>",
"       </td>",
"       <td>",
"        Cerebral CT",
"       </td>",
"       <td>",
"        Hemiparesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rabe et al, 2006",
"       </td>",
"       <td>",
"        54/M",
"       </td>",
"       <td>",
"        <p>",
"         Portal vein cavernoma",
"        </p>",
"        <p>",
"         Patent foramen ovale",
"        </p>",
"       </td>",
"       <td>",
"        Balloon revision of obstructed metallic biliary stent",
"       </td>",
"       <td>",
"        <p>",
"         Brisk bleeding",
"        </p>",
"        <p>",
"         Venous air embolism",
"        </p>",
"        <p>",
"         Cardiorespiratory arrest",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Echocardiography",
"        </p>",
"        <p>",
"         Autopsy",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tan et al, 2008",
"       </td>",
"       <td>",
"        82/F",
"       </td>",
"       <td>",
"        Ampulloma of Vater's papilla",
"       </td>",
"       <td>",
"        Metallic biliary stent",
"       </td>",
"       <td>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Cardiorespiratory arrest",
"        </p>",
"        <p>",
"         Cerebral ischemia",
"        </p>",
"       </td>",
"       <td>",
"        Body scan (thoraco-abdominal and cerebral CT)",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bisceglia et al, 2009",
"       </td>",
"       <td>",
"        78/M",
"       </td>",
"       <td>",
"        <p>",
"         Bile duct stone",
"        </p>",
"        <p>",
"         Cholangitis and liver abscesses",
"        </p>",
"        <p>",
"         Biliary-duodenal fistula",
"        </p>",
"       </td>",
"       <td>",
"        Stone extraction",
"       </td>",
"       <td>",
"        <p>",
"         Veno-biliary fistula",
"        </p>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Cardiorespiratory arrest",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Thoraco-abdominal and cerebral CT",
"        </p>",
"        <p>",
"         Autopsy findings",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Romberg, 2009",
"       </td>",
"       <td>",
"        53/M",
"       </td>",
"       <td>",
"        Bile duct stone",
"       </td>",
"       <td>",
"        Mechanical lithotripsy",
"       </td>",
"       <td>",
"        <p>",
"         Moderate bleeding",
"        </p>",
"        <p>",
"         Porto-biliary fistula",
"        </p>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Hypoxemia, shock, and unconsciousness",
"        </p>",
"       </td>",
"       <td>",
"        Transesophageal echocardiography",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rangappa et al, 2009",
"       </td>",
"       <td>",
"        50/F",
"       </td>",
"       <td>",
"        <p>",
"         Bile duct stone",
"        </p>",
"        <p>",
"         Cholecystectomy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Widening of sphincterotomy",
"        </p>",
"        <p>",
"         Stone extraction",
"        </p>",
"       </td>",
"       <td>",
"        Venous and arterial air embolism",
"       </td>",
"       <td>",
"        <p>",
"         Cerebral CT",
"        </p>",
"        <p>",
"         Autopsy",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cha et al, 2010",
"       </td>",
"       <td>",
"        50/F",
"       </td>",
"       <td>",
"        <p>",
"         Bile duct stones",
"        </p>",
"        <p>",
"         Choledocoduodenostomy",
"        </p>",
"        <p>",
"         Liver abscesses",
"        </p>",
"       </td>",
"       <td>",
"        Stone extraction",
"       </td>",
"       <td>",
"        <p>",
"         Venous air embolism",
"        </p>",
"        <p>",
"         Cardiorespiratory arrest",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Chest x-ray",
"        </p>",
"        <p>",
"         Abdominal CT",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Going et al, 2010",
"       </td>",
"       <td>",
"        72/F",
"       </td>",
"       <td>",
"        Cholangiocarcinoma",
"       </td>",
"       <td>",
"        Cholangioscopy ERCP",
"       </td>",
"       <td>",
"        <p>",
"         Venous air embolism",
"        </p>",
"        <p>",
"         Cardiorespiratory arrest",
"        </p>",
"        <p>",
"         Cerebral ischemia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Abdominal x-ray",
"        </p>",
"        <p>",
"         Transesophageal echocardiography",
"        </p>",
"        <p>",
"         Cerebral MRI",
"        </p>",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arguelles Garcia et al, 2010",
"       </td>",
"       <td>",
"        82/M",
"       </td>",
"       <td>",
"        <p>",
"         Previous ES",
"        </p>",
"        <p>",
"         Cholangitis",
"        </p>",
"        <p>",
"         Bile duct stones",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Balloon dilatation",
"        </p>",
"        <p>",
"         Stone extraction",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Hypoxemia, shock and hemiparesis",
"        </p>",
"        <p>",
"         Cerebral ischemia",
"        </p>",
"       </td>",
"       <td>",
"        Cerebral CT",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Van Boxel et al, 2010",
"       </td>",
"       <td>",
"        82/M",
"       </td>",
"       <td>",
"        <p>",
"         Bile duct stones",
"        </p>",
"        <p>",
"         Bile duct stent",
"        </p>",
"       </td>",
"       <td>",
"        Removal of bile duct stent",
"       </td>",
"       <td>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Myocardial and cerebral ischemia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Electrocardiogram",
"        </p>",
"        <p>",
"         Cerebral CT",
"        </p>",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finsterer et al, 2010",
"       </td>",
"       <td>",
"        59/F",
"       </td>",
"       <td>",
"        <p>",
"         Choledochojejunostomy",
"        </p>",
"        <p>",
"         Recurrent cholangitis and liver abscesses",
"        </p>",
"       </td>",
"       <td>",
"        Removal of bile duct stent",
"       </td>",
"       <td>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Hypoxemia and shock",
"        </p>",
"       </td>",
"       <td>",
"        Thoraco-abdominal and cerebral CT",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mal et al, 2010",
"       </td>",
"       <td>",
"        78/F",
"       </td>",
"       <td>",
"        <p>",
"         Cholangitis",
"        </p>",
"        <p>",
"         Bilio-digestive anastomosis",
"        </p>",
"       </td>",
"       <td>",
"        Dilatation of bilio-digestive",
"       </td>",
"       <td>",
"        <p>",
"         Mild bleeding",
"        </p>",
"        <p>",
"         Venous air embolism",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Echocardiography",
"        </p>",
"        <p>",
"         Autopsy",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Di Pisa et al, 2011",
"       </td>",
"       <td>",
"        8/M",
"       </td>",
"       <td>",
"        <p>",
"         Portal cavernoma",
"        </p>",
"        <p>",
"         Post-sphincterotomy bleeding",
"        </p>",
"       </td>",
"       <td>",
"        Removal of covered metal stent",
"       </td>",
"       <td>",
"        <p>",
"         Moderate bleeding",
"        </p>",
"        <p>",
"         Venous air embolism",
"        </p>",
"        <p>",
"         Cardiorespiratory arrest",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Transesophageal echocardiography",
"        </p>",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jow et al, 2011",
"       </td>",
"       <td>",
"        65/M",
"       </td>",
"       <td>",
"        <p>",
"         Chronic pancreatitis",
"        </p>",
"        <p>",
"         Pancreatic pseudocyst",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pancreatic sphincterotomy",
"        </p>",
"        <p>",
"         Pancreatic stent",
"        </p>",
"        <p>",
"         EUS-guided cyst-gastrostomy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Venous air embolism",
"        </p>",
"        <p>",
"         Cardiorespiratory arrest",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Radiographs postmortem",
"        </p>",
"        <p>",
"         Autopsy",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bechi et al, 2011",
"       </td>",
"       <td>",
"        79/F",
"       </td>",
"       <td>",
"        Bile duct stones",
"       </td>",
"       <td>",
"        ES",
"       </td>",
"       <td>",
"        Venous air embolism",
"       </td>",
"       <td>",
"        Echocardiography",
"       </td>",
"       <td>",
"        Recovered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maccarone et al, 2011",
"       </td>",
"       <td>",
"        45/M",
"       </td>",
"       <td>",
"        Bile duct stones",
"       </td>",
"       <td>",
"        Rendezvous technique",
"       </td>",
"       <td>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Shock and cerebral ischemia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Transesophageal echocardiography",
"        </p>",
"        <p>",
"         Brain MRI",
"        </p>",
"       </td>",
"       <td>",
"        Near complete recovery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nern et al, 2012",
"       </td>",
"       <td>",
"        58/F",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"font-family: verdana,sans-serif; color: #000000; font-size: 9pt;\">",
"          Suspected Klatskin tumor",
"         </span>",
"        </p>",
"        <p>",
"         <span style=\"font-family: verdana,sans-serif; color: #000000; font-size: 9pt;\">",
"          Echinococcus of the liver",
"         </span>",
"        </p>",
"        <p>",
"         Patent foramen ovale",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"font-family: arial,sans-serif; color: red; font-size: 9pt;\">",
"         </span>",
"         Liver biopsy",
"        </p>",
"        <p>",
"         Biliary&nbsp;stent&nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Venous and arterial air embolism",
"        </p>",
"        <p>",
"         Cerebral infarctions",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Body scan (thoraco-abdominal and cerebral CT)",
"        </p>",
"        <p>",
"         Autopsy",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Death",
"        </strong>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ES: endoscopic sphincterotomy; PTBD: percutaneous transhepatic biliary drainage; MRI: magnetic resonance imaging; CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_60_40911=[""].join("\n");
var outline_f39_60_40911=null;
